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ABSTRACT 
Susan C. Wu 
Molecular function and regulation of the histone methyltransferase, Ezh2 
(Under the direction of Dr. Yi Zhang) 
 
 EZH2 (Enhancer of zeste 2) is an important developmental regulator that plays an 
important role in numerous biological processes including multi-cellular development, stem 
cell biology, and cancer development.  As an H3K27 histone methyltransferase, EZH2 is an 
epigenetic regulator that functions to repress transcription.  It is often upregulated in human 
cancers and its oncogenic potential is thought to stem from its role in cell proliferation and 
repression of tumor suppressor genes.  Hence, regulation of EZH2 function is important for 
normal cellular growth.  In this dissertation, the molecular function and regulation of EZH2 
are investigated.  I demonstrate that genomic targets of EZH2 not only include protein-
coding genes, but also encompasses lncRNAs (long non-coding RNAs), a class of RNAs that 
account for the vast majority of the mammalian transcriptome.  Using a custom-designed 
microarray, I show that lncRNAs exhibit cell type specific expression patterns and that their 
expression levels correlate with the epigenetic marks, H3K4me3 and H3K27me3.  Consistent 
with this finding, knockdown of EZH2 results in the derepression of many lncRNAs.  With 
regard to EZH2 regulation, I provide evidence that EZH2 contains numerous phosphorylation 
sites although their functions are currently unknown.  Characterization of two 
phosphorylation sites, threonines 345 and 487, has revealed important aspects of EZH2 
 iv 
regulation.  Through in vitro and in vivo experiments, I show that phosphorylation of these 
two residues can be mediated by the cyclin dependent kinase, CDK1.  Consistent with the 
cell cycle phase that exhibits peak CDK1 activity, mitotic cell extracts are enriched for 
phospho-EZH2.  Importantly, when EZH2 is phosphorylated at T345 and T487, the stability 
of the protein is compromised as EZH2 is targeted for ubiquitination and degradation by the 
proteasome.  Collectively, this work reveals a novel class of EZH2 targets and provides a 
mechanism by which EZH2 protein levels are regulated in the cell.   
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CHAPTER 1 
 
INTRODUCTION 
 
 
 
 
 
Minor sections have been adapted from the following sources: 
Wu, S. C., and Zhang, Y. (2010). Active DNA demethylation: many roads lead to Rome. 
Nature Reviews Molecular Cell Biology 11, 607-620. 
 
Wu, S. C., and Zhang, Y. (2009). Minireview: Role of protein methylation and demethylation 
in nuclear hormone signaling. Molecular Endocrinology 23, 1323-1334.
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INTRODUCTION 
 
In higher eukaryotes, every cell in a multicellular organism is ultimately derived from 
a single totipotent cell.  During development, this totipotent cell divides and subsequent 
daughter cells are required to make cell fate decisions either choosing to remain totipotent or 
alternatively, committing to a specific cell lineage.  The final result is the production of 
distinct cell types and tissues that make up an organism.   
One of the most fascinating features of this process is the relative stability of the 
committed state during the development of multicellular organisms.  Commitment to a 
specific cell lineage is established early on, long before the appearance of any specialized 
functions.  Once committed, cells retain a developmental “memory” and rarely change their 
fates even after undergoing many rounds of cell division.  A tremendous amount of research 
has attributed epigenetics to be a major player in both the cell commitment and cell memory 
process. 
 The term “epigenetics” was coined by C.H. Waddington in the early 1940s and was 
originally defined as “the branch of biology which studies the causal interactions between 
genes and their products, which bring the phenotype into being” (Waddington, 1942).  
Historically speaking, events that could not be explained by genetic principles were often 
classified as “epigenetic”.  Research over the past few decades have provided us with a much 
clearer understanding as to how such phenotypes can arise even when they appear to violate 
Mendel’s laws.  Today, an epigenetic trait is defined as a “stably heritable phenotype 
resulting from changes in a chromosome without alterations in the DNA sequence” (Berger 
et al., 2009). 
 3 
 
EPIGENETIC REGULATION OF GENE EXPRESSION 
 Eukaryotic chromatin contains a wealth of information required for the growth and 
development of a multicellular organism.  This information is not only stored genetically 
within the DNA sequence itself but also epigenetically through molecular mechanisms that 
include DNA methylation, chromatin remodeling, and post-translational modifications of 
histone proteins (Jaenisch and Bird, 2003; Jenuwein and Allis, 2001).  Although every 
nucleotide in the genome has the potential to be transcribed (Birney et al., 2007), the 
presence or absence of specific epigenetic marks influences gene expression resulting in a 
transcriptional program that specifies for a particular cell type.  For example, in embyronic 
stem (ES) cells, active gene expression marks are found at genes associated with 
pluripotency, while repressive marks are found at lineage-specific genes.  Thus, different cell 
types can be defined by their epigenetic and gene expression profiles. 
One well characterized epigenetic mechanism involves methylation of DNA which is 
associated with transcriptional silencing.  In mammals, DNA methylation occurs 
predominantly within the context of CpG (cytosine followed by guanine) dinucleotides, 
while DNA methylation in plants can occur at cytosine bases in diverse sequence contexts 
(Law and Jacobsen, 2010).  The enzymes responsible for this modification, DNA 
methyltransferases (DNMTs), are well-characterized and conserved in mammals and plants 
(Law and Jacobsen, 2010).  DNMTs fall under two categories: de novo and maintenance 
(Goll and Bestor, 2005). Patterns of DNA methylation are initially established by the de novo 
methyltransferases, Dnmt3a and Dnmt3b, during the blastocyst stage of embryonic 
development (Okano et al., 1999; Okano et al., 1998) (Figure 1.1).  These methyl marks are 
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faithfully maintained during cell divisions through the action of the maintenance 
methyltransferase, Dnmt1, which has a preference for hemi-methylated DNA (Bestor et al., 
1988; Bestor and Ingram, 1983; Hermann et al., 2004).  Both the establishment and 
maintenance of DNA methylation patterns are crucial for development as mice deficient in 
Dnmt3b or Dnmt1 are embryonic lethal (Li et al., 1992; Okano et al., 1999) while Dnmt3a 
null mice die by 4 weeks of age (Okano et al., 1999). 
Although DNA methylation has been viewed as a stable epigenetic mark, studies in 
the past decade have revealed that this modification is not as static as once believed.  Loss of 
DNA methylation, or DNA demethylation, has been observed in specific contexts and can 
occur through active or passive mechanisms (Figure 1.1).  Active DNA demethylation refers 
to the enzymatic process that results in the removal of the methyl group from 5-
methylcytosine (5meC) by breaking a carbon-carbon bond.  On the other hand, passive DNA 
demethylation refers to the loss of the methyl group from 5meC when Dnmt1 is inhibited or 
absent during successive rounds of DNA replication.  While passive DNA demethylation is 
generally understood and accepted, the subject of active DNA demethylation has been quite 
controversial (Ooi and Bestor, 2008; Wu and Zhang, 2010). 
In addition to DNA methylation, genes can be epigenetically regulated by post-
translational modifications of histone proteins.  The eukaryotic cell contains about two 
meters of DNA that must be condensed to fit into the nucleus as well as organized in order to 
facilitate DNA-templated processes including replication, transcription, and repair.  To solve 
this problem, genomic DNA is complexed with histone and chromosomal proteins to form 
chromatin.  The fundamental unit of chromatin is the nucleosome which consists of 146 base 
pairs of DNA wrapped around an octamer of four core histone proteins, H2A, H2B, H3, and 
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H4 (Kornberg and Lorch, 1999).  Once believed to function solely as structural elements, it 
has become evident that histones play critical roles in regulating chromatin dynamics to 
modulate gene expression.   
Extending from the globular domain of histone proteins are the unstructured N-
terminal tails which are subject to post-translational modifications including acetylation, 
methylation, phosphorylation, and ubiquitination.  Covalently-modified histones can alter 
chromatin dynamics to control the accessibility of transcription machinery or function as 
binding sites to recruit regulatory proteins.  Because of their ability to modulate gene 
expression, histone modifying enzymes have a broad impact on normal cellular processes 
and thus their functions are generally regulated in the cell.  The consequences of 
misregulation are exemplified by the observation that many histone modifying enzymes are 
overexpressed in a broad range of human cancers (Schneider et al., 2002). 
 
HISTONE METHYLATION 
Histone methylation, which can occur on lysine and arginine residues, has been 
implicated in many biological processes including transcriptional regulation, heterochromatin 
formation, X-inactivation, and genomic imprinting (Bedford and Richard, 2005; Martin and 
Zhang, 2005).  Lysine residues can accept up to three methyl groups while arginine residues 
can be mono-methylated, symmetrically di-methylated, or asymmetrically di-methylated 
(Figure 1.2).  Thus far, there are at least 5 arginine residues (H3R2, H3R8, H3R17, H3R26, 
and H4R3), and 6 lysines residues (H3K4, H3K9, H3K27, H3K36, H3K79, and H4K20) on 
histones H3 and H4 that can be methylated in mammals (Klose and Zhang, 2007).  All of 
these residues are located within the unstructured N-terminal tail of the histone protein with 
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the exception of H3K79 which resides in the globular domain (Feng et al., 2002).  Given that 
the scope of this work concerns lysine methylation of histone proteins, only this modification 
will be discussed in further detail.  For more information regarding arginine methylation, the 
author would like to direct the reader to the following in depth reviews (Bedford, 2007; 
Bedford and Richard, 2005; Wysocka et al., 2006).   
Depending on the residue modified, lysine methylation of histone proteins can have 
both positive and negative effects on transcription.  Methylation of K4, K36, and K79 has 
been correlated with gene activation, while methylation of K9, K27, and H4K20 are 
considered repressive marks.  Unlike acetylation and phosphorylation, methylation does not 
affect the overall charge of the histone molecule and thus is not believed to regulate gene 
expression by disrupting histone-DNA interactions.  However, in some cases, methylation 
can serve as a binding site for the recruitment of chromodomain-containing proteins that bind 
to methylated histones.  For example, heterochromatin regions are enriched with 
heterochromatin protein 1 (HP1) which possesses a chromodomain that specifically binds to 
tri- and di-methylated K9, a mark associated with repression (Bannister et al., 2001; Lachner 
et al., 2001).  Additionally, the chromodomain of Eaf3, a member of the of histone 
deacetylase complex RPD3, binds to K36 methylation (Keogh et al., 2005).  Although it has 
become apparent that histone methylation functions more as an “information storage mark” 
to recruit other regulatory proteins that affect gene expression, the precise mechanisms by 
which histone methylation regulates transcription is poorly understood. 
Lysine methylation of histone proteins is carried out by a group of enzymes called 
histone methyltransferases (HMTs) which catalyze the transfer of a methyl group from the 
methyl donor S-adenosyl-L-methionine (SAM) to the ε-NH2 group of the lysine residue 
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(Martin and Zhang, 2005).  With the exception of Dot1/Dot1L, all lysine HMTs possess the 
evolutionarily conserved SET domain which was named after three Drosophila proteins 
discovered to contain this conserved sequence: Suppressor of variegation 3-9 (Su(var)3-9), 
Enhancer of zester (E(z)), and Trithorax (Trx) (Dillon et al., 2005).  Although the SET 
domain is responsible for the enzymatic activity of lysine HMTs and is present in about 60 
human proteins, only a fraction of these proteins have been shown to possess the ability to 
methylate histones.  Furthermore, the name histone methyltransferase is a bit of a misnomer 
as many of these enzymes have also been shown to be target non-histone substrates as well 
(Huang and Berger, 2008).   
Unlike histone acetylation and phosphorylation, the reversibility of histone 
methylation was hotly debated for many years.  In fact, it was widely believed that histone 
methylation was a relatively stable mark due to the strength of the carbon-nitrogen bond that 
would have to be broken to facilitate demethylation.  Thus, it was unclear whether any 
enzymes possessing such high catalytic power existed.  Furthermore, early biochemical 
studies concluded that histone methylation was quite stable in the cell due to the observation 
that the turnover rate of methylated histones was similar to total histones (Byvoet et al., 
1972). 
However, this notion was shown to be wrong upon the proof of principle discoveries 
of histone demethylases.  The first lysine histone demethylase identified was LSD1 (lysine 
specific demethylase 1) which can demethylate mono- and di-methyl H3K4 and H3K9 by 
amine oxidation in a flavin-dependent manner (Shi et al., 2004).  This mechanism requires a 
protonated nitrogen thus precluding demethylation of tri-methylated substrates.  Furthermore, 
 8 
given that there are only two LSD1 homologs in mammals, a larger family of demethylases 
that included enzymes capable of removing the tri-methyl mark was likely to exist.   
Shortly after the discovery of LSD1, the Jumonji C (JmjC) domain-containing 
demethylases were discovered through biochemical methods involving an assay where 
demethylase activity was detected by the release of radiolabeled formaldehyde (Tsukada et 
al., 2006).  JHDM1A (Jumonji domain-containing histone demethylase 1A), the founding 
member of this family, catalyzes the removal of mono- and di-methyl K36, releasing 
formaldehyde as a byproduct.  Its activity is dependent on iron and α-ketoglutarate as well as 
a highly conserved histidine residue located within the JmjC domain (Tsukada et al., 2006).  
Subsequent phylogenetic analysis of JmjC domain-containing proteins demonstrated that this 
family is highly conserved in eukaryotes ranging from humans to budding yeast (Klose et al., 
2006a).  Since then, many mammalian JmjC domain-containing proteins have been 
demonstrated to possess demethylase activity (Agger et al., 2007; Cloos et al., 2006; Klose et 
al., 2006b; Klose et al., 2007; Lan et al., 2007; Lee et al., 2007; Whetstine et al., 2006; 
Yamane et al., 2007; Yamane et al., 2006) including several that are specific for tri-
methylated lysines (Cloos et al., 2006; Klose et al., 2006b; Klose et al., 2007; Yamane et al., 
2007).  
 
POLYCOMB GROUP OF PROTEINS 
In the early 1940s, Eleanor H. Slifer isolated a Drosophila mutant that exhibited an 
interesting phenotype.  Normal male fruit flies possess sex-combs, a structure made up of 
about ten heavy, curved, black bristles at each of their forelegs that are used to grasp females 
during the mating process.  However, the sterile male mutants that Slifer isolated possessed 
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sex-combs at each of its six legs.  After a series of appropriate crosses, she attributed the 
phenotype to a recessive mutation that she named extra sex combs (esc) (Slifer, 1942).  In 
1947, a second mutation also causing the extra sex combs phenotype was discovered by 
Pamela Lewis and called Polycomb (Pc).  The mutation produced the phenotype when 
heterozygous, but was lethal when homozygous.   
Utilizing the power of Drosophila genetics, this seminal work paved way for the 
isolation of many other mutations (both dominant and recessive) that caused the extra sex 
combs phenotype.  These genes whose mutations are responsible for this phenotype, are now 
collectively known as the Polycomb group and comprise of about 15 members that are highly 
conserved in organisms including flies, plants, and mammals.  As suggested by early work in 
fruit flies, the Polycomb group of genes are responsible for repressing developmental control 
genes that establish cell fate in the developing embryo.  Their importance in development is 
highlighted by the observation that deletion of some Polycomb genes results in early 
embryonic lethality in mice (Faust et al., 1995; Niswander et al., 1988; O'Carroll et al., 2001; 
Pasini et al., 2004). 
Around the time Pamela Lewis discovered the Pc mutant fly, her husband, the Nobel 
Prize-winning geneticist, Ed Lewis, discovered fruit fly mutants that exhibited an abnormal 
segmentation pattern where anterior structures were often shifted to the posterior.  Further 
mutational studies indicated that several genomically linked genes were responsible for these 
shifts in cell fate determination.  These genes became known as the Bithorax complex and 
genetic evidence suggested that Polycomb proteins functioned to repress this cluster of 
genes.  Since his seminal work, other developmental gene clusters have been identified in 
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Drosophila including Ultrabithorax and Antennapedia and are collectively known as HOX 
genes. 
HOX genes encode transcription factors that specify the anterior-posterior axis and 
segment identity in metazoan organisms during embryonic development.  These clusters are 
spatially and temporally expressed through the actions of a group of activator proteins known 
as Trithorax proteins.  Once HOX genes have done their work, they are permanently 
suppressed by Polycomb proteins.  This suppression prevents structures such as sex combs 
and wings from forming in the wrong body segments.  Thus, the functional relationship 
between Trithorax and Polycomb proteins is antagonistic.  Importantly, the suppression of 
these developmental regulators by Polycomb proteins is not only permanent during the 
lifespan of the cell, but is also heritable and passed down to all the cells’ daughters 
throughout the lifetime of the organism.  This remarkable phenomenon has thus attracted 
many people to study how Polycomb proteins contribute to the “cellular memory” process. 
 
POLYCOMB REPRESSIVE COMPLEXES 
Although scientists had known for half a century that the Polycomb group of genes 
play a crucial role in establishing the body plans of organisms from fruit flies to humans, 
exactly how this is achieved was poorly understood.  Without the sequences to the actual 
genes, the field struggled to make any progress in understanding the molecular mechanism.  
It was not until 1991 when the first Polycomb gene was cloned by Renato Paro who achieved 
this feat with the Polycomb (Pc) gene itself (Paro and Hogness, 1991).  Analysis of the Pc 
gene product provided the first clue as to how Polycomb proteins may function.  The protein 
sequence contains a stretch of 37 amino acids that are highly similar to the chromatin-binding 
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domain of HP1.  This led to the idea that Polycomb may repress gene activity by binding to 
chromatin.   
Subsequently, the nucleotide sequences for other Polycomb genes were determined 
which set the stage for extensive sequence analysis and biochemical work to understand how 
Polycomb proteins functioned.  Early genetic studies provided the initial clue that Polycomb 
proteins functioned together in multi-protein complexes.  Today, Polycomb-mediated gene 
silencing is believed to transpire primarily through the actions of two distinct complexes that 
regulate of chromatin structure by post-translationally modifying histone proteins. 
The first complex, PRC1 (Polycomb repressive complex 1) was discovered by Robert 
Kingston’s group in 1999 and was biochemically purified from Drosophila embryos.  Using 
antibodies against candidate Polycomb proteins, western blot analysis revealed that PC 
(Polycomb), PSC (Posterior sex combs), PH (Polyhomeotic), and SCM (Sex comb on 
midleg) were present in the purified complex.  Furthermore, the purified complex was able to 
inhibit chromatin remodeling suggesting that PRC1 functioned by binding to chromatin 
(Shao et al., 1999). 
A few years later, mass spectrometry identified additional proteins present in the 
original complex, but only dRING1 (Drosophila RING protein 1) was present at a similar 
stoichiometric level as PC/PSC/PH, while SCM was present at sub-stoichiometric amounts 
(Saurin et al., 2001).  With this in mind, Kingston and colleagues successfully reconstituted 
the core PRC1 complex containing PC, PSC, PH, and dRING1 (Figure 1.3) and found that it 
was functional in the inhibition of chromatin remodeling (Francis et al., 2001). 
The mammalian homologues of these four proteins, PC, BMI1 (B lymphoma Mo-
MLV insertion region 1 homolog), PH, and RING1B, also form a stable and functional 
 12 
complex (Lavigne et al., 2004; Levine et al., 2002).  RING1B is an E3-ubiquitin ligase 
capable of mono-ubiqutinating H2A at lysine K119, a mark associated with repression, while 
BMI1 can stimulate this activity (Cao et al., 2005; Kallin et al., 2009; Wang et al., 2004a).  
Reconstituted mammalian PRC1 complexes are functional and capable of inhibiting ATP-
dependent chromatin remodeling, compacting chromatin, and repressing transcription in vitro 
(Francis et al., 2004; Francis et al., 2001; King et al., 2005). 
Shortly after the discovery of PRC1, four groups identified a second complex of 
Polycomb group proteins named PRC2 in both Drosophila and mammals (Cao et al., 2002; 
Czermin et al., 2002; Kuzmichev et al., 2002; Muller et al., 2002).  Like PRC1, PRC2 
contributes to Polycomb-mediated silencing by modifying chromatin.  Specifically, the key 
observation was that one of the PRC2 components was EZH2 (Enhancer of zeste 2) which 
possesses a SET domain that confers H3K27 methyltransferase activity.  Subsequent work 
involving reconstitution of mammalian PRC2 led to the knowledge that the minimum core 
components for activity are EZH2, SUZ12 (suppressor of zeste 12), and EED (embryonic 
ectoderm development) while other components such as RBAP46/48 (RB associated protein 
46/48) could stimulate its activity (Cao and Zhang, 2004) (Figure 1.4). 
Preliminary biochemical characterization of PRC2 indicated that these complexes 
functioned to promote gene repression by regulating chromatin structure.  Additional work 
revealed that other proteins including DNMTs, HDAC1 (histone deacetylase 1), and SIRT1 
(silent mating type information regulation 2 homolog) can transiently interact with PRC2 
(Caretti et al., 2004; Kuzmichev et al., 2005; Vire et al., 2006), but their impact on PRC2 
function is presently unclear.  In addition to the core components, the PRC2 complex also 
contains other proteins that are stably associated which are discussed below. 
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AEBP2 (adipocyte enhancer binding protein 2) was identified in one of the initial 
purifications of PRC2 (Cao et al., 2002).  Reconstitution of PRC2 with different subunits 
demonstrated that AEBP2 interacts with several components of PRC2 to enhance its HMT 
activity (Cao and Zhang, 2004).  Given that AEBP2 contains a zinc-finger, it was initially 
postulated that it functioned to recruit PRC2 to DNA.  However, it appears to bind to DNA 
with low specificity (Kim et al., 2009) suggesting that other factors may play a larger role in 
the recruitment of PRC2 to target genes (see below).  Nonetheless, AEBP2 stably participates 
in some PRC2 complexes as it co-localizes with PRC2 at a subset of target gene promoters 
(Kim et al., 2009).   
In addition to AEBP2, PCL (Polycomb-like) proteins can also exist in the PRC2 
complex through interactions with EZH2 and to some extent, SUZ12 and RbAp46/48 
(Nekrasov et al., 2007).  In Drosophila, only one PCL protein is present and is responsible 
for the development of normal segmentation patterns of the fly (Duncan, 1982).  There are 
three mammalian homologues, PCL1, PCL2, and PCL3 (also known as CBX2, CBX4, and 
CBX6-8) which appear to be expressed in a tissue-specific manner (Walker et al., 2010).  All 
PCL proteins share conserved protein motifs: a tudor domain and two plant homeodomain 
(PHD) finger proteins (Wang et al., 2004c).  Consistent with the notion that some PRC2 
complexes contain PCL proteins, genome-wide studies have found that PCL2 is bound at a 
subset of PRC2 target genes (Li et al., 2010; Walker et al., 2010).  The function of PCL 
proteins within the PRC2 complex is presently unclear although several studies have 
suggested that they can affect the enzymatic activity of PRC2 (Nekrasov et al., 2007; Sarma 
et al., 2008) as well as the recruitment of PRC2 to target genes (Savla et al., 2008; Walker et 
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al., 2010).  Discrepancies between these studies might be explained by the redundancy of 
mammalian PCL proteins and their cell-specific expression patterns.    
JARID2 is a member of the Jumonji family of proteins which have been implicated in 
the demethylation of histone proteins.  Unlike other members of the Jumonji family, it lacks 
the key residues necessary for cofactor binding and thus does not possess enzymatic activity.  
Interestingly, several biochemical studies have not only demonstrated a direct interaction 
between JARID2 and EZH2, but also that JARID2 and PRC2 share a large overlap of target 
genes (Landeira et al., 2010; Li et al., 2010; Pasini et al., 2010; Peng et al., 2009; Shen et al., 
2009).  Although JARID2 depletion results in impaired recruitment of PRC2, global levels of 
H3K27me3 levels were only modestly affected (Landeira et al., 2010; Shen et al., 2009).  
This raised questions regarding the significance of JARID2 in PRC2 recruitment.  
Furthermore, if JARID2 is a major player in the recruitment of PRC2 to target genes, it is 
expected that JARID2 null mice would exhibit similar phenotypes compared to mice where 
components of the PRC2 complex are deleted.  While deletion of JARID2 in mice results in 
embryonic lethality, these embryos develop to a much later stage than EZH2, SUZ12, or 
EED null embryos (Faust et al., 1995; Jung et al., 2005; Kitajima et al., 1999; Niswander et 
al., 1988; O'Carroll et al., 2001; Pasini et al., 2004).  These inconsistencies highlight the need 
for further work in evaluating the contribution of JARID2 to PRC2 function.   
Although this section only discusses alternative subunits of the PRC2 complex 
(Figure 1.4), accumulating evidence has demonstrated that the PRC1 complex can contain 
other proteins in addition to the core components.  These observations have led to the 
emerging theme that Polycomb complexes are composed of core components to which 
various proteins can be added in order to confer distinct functions.  The composition of these 
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complexes may vary from cell type to cell type in order to accommodate the epigenetic 
requirements of a particular cell. 
 
FUNCTIONS OF H3K27 METHYLATION 
As discussed above, methylation of H3K27 is mediated by the PRC2 complex 
through the catalytic activity of EZH2.  This modification is conserved in many eukaryotes 
including mammals, flies, worms, and plants, but is absent in budding yeast (Cao et al., 
2002).  In embryonic stem (ES) cells, H3K27 methylation is quite abundant where roughly 
50% of total histone H3 is di-methylated, 15% tri-methylated, and 15% mono-methylated 
(Peters et al., 2003).  H3K27 methylation is not only stable, but also processive where tri-
methylated H3K27 results from the mono-methylation of di-methylated H3K27.   
The advent of novel technologies including chromatin immunoprecipitation (ChIP) 
coupled with expression microarray analysis (ChIP-chip) or deep sequencing (ChIP-Seq) has 
allowed for genome-wide mapping of histone modifications, histone modifiers, and 
transcription factors.  With these tools, we now know that regions of tri-methylated H3K27 
enrichment can be divided into two groups based on their size.  Some domains such as the 
HOX clusters can span over 100 kilobases in length while smaller domains of tri-methylated 
H3K27 enrichment encompass only a few kilobases (Boyer et al., 2006; Hawkins et al., 
2010; Squazzo et al., 2006; Zhao et al., 2007).  Levels of H3K27 tri-methylation peak at the 
transcription start site of genes (Pan et al., 2007; Zhao et al., 2007) but domains of H3K27 
tri-methylation can also be found at intergenic regions (Cui et al., 2009; Zhao et al., 2007), 
sub-telomeric regions (Rosenfeld et al., 2009), and long terminal repeat retrotransposons 
(Leeb et al., 2010). 
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The availability of genome-wide maps has also provided evidence that many genomic 
loci do not contain a single type of histone modification, but instead contain a combination of 
modifications.  These combinations of histone modifications or the “histone code” (Strahl 
and Allis, 2000) is one possible way for the cell to meet its diverse transcriptional needs.  
One set of histone modifications that has attracted much attention is the bivalent domain 
which are regions that contain both the repressive tri-methylated H3K27 mark and active tri-
methylated H3K4 mark (Bernstein et al., 2006).  Bivalent domains were originally 
discovered in ES cells, but have also been observed in somatic cells albeit at lower levels 
(Mikkelsen et al., 2007; Mohn et al., 2008).  Genes that are bivalent at their promoters are not 
considered to be transcriptionally active, but instead are thought to be “poised” to commit to 
either the active or repressed state by losing one of the two opposing marks (Figure 1.5).  
After losing the tri-methylated H3K4 mark, repression is then mediated by the pre-existing 
tri-methylated H3K27 mark.  Furthermore, enforced repression may be executed by 
extending the length of the tri-methylated H3K27 domain as well as by the addition of other 
repressive marks such as tri-methyl H3K9 (Hawkins et al., 2010) or DNA methylation 
(Brunner et al., 2009; Meissner et al., 2008; Mohn et al., 2008).    
Similar to other sites of methylation, the use of different methylation states offers the 
ability to confer distinct functional outcomes.   While enrichment of tri-methylated H3K27 at 
gene promoters is associated with transcriptional repression (Barski et al., 2007), it appears 
that di-methylated H3K27 is of limited importance for gene repression (Sarma et al., 2008).  
Instead, di-methylated H3K27 may function as a stable substrate allowing for the subsequent 
formation of tri-methylated H3K27 to occur in a rapid manner.  In addition to methylation, 
H3K27 can also be acetylated and thus di-methylation of H3K27 may also function to 
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prevent acetylation of this site.  Indeed, H3K27 acetylation is enriched in the absence of 
PRC2 and is thought to be antagonistic to Polycomb mediated silencing (Tie et al., 2009).  
While di- and tri-methylated H3K27 has been associated with facultative heterochromatin 
(heterochromatin that is regulated in a cell type specific manner), mono-methylation of 
H3K27 is associated with constitutive heterochromatin (gene-poor regions of the genome 
that are stably repressed).  Oddly, while di- and tri-methylated H3K27 are found at gene 
promoters, enrichment of mono-methyl H3K27 has been observed within gene bodies and 
correlates with actively transcribed genes (Cui et al., 2009).  The significance of this finding 
is unclear at the present. 
 Thus far, PRC2 contains the only known enzymatic activity capable of di- and tri-
methylation of H3K27.  In mammals, how mono-methylation of H3K27 arises is currently 
unknown as this modification is still detected in cells bearing non-functional PRC2 (Pasini et 
al., 2007; Schoeftner et al., 2006).  Although the plant enzymes, ATXR5 and ATXR6, have 
the capacity to lay down this modification (Jacob et al., 2009), they function independently 
of PRC2 and are not conserved in mammals. 
 The molecular mechanism by which H3K27 tri-methylation exerts transcriptional 
repression is not well understood.  As discussed earlier, histone modifications can exert their 
function either by altering the chromatin structure or by recruiting other regulatory proteins.  
Given that lysine methylation does not biophysically change DNA-histone interactions in any 
obvious way, it is likely that H3K27 tri-methylation recruits additional factors that contribute 
to transcriptional repression.  One attractive model that has persisted over the years is that tri-
methylated H3K27 serves to recruit PRC1.  Consistent with this, PC (a component of the 
PRC1 complex) possesses a chromodomain that can bind to tri-methylated H3K27 (Cao et 
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al., 2002) allowing for the recruitment of PRC1 to ubiquitinate H2A (Figure 1.6).  How 
stable repression is achieved by ubiquitinated H2A is unclear.  In any case, it is widely 
accepted that PRC2 functions upstream of PRC1.  
 Interestingly, a substantial fraction of tri-methylated H3K27 promoters also contain 
RNA polymerase (Pol) II that is phosphorylated at serine 5 of its C-terminal domain (Stock 
et al., 2007).  Low levels of transcripts have also been detected from these promoters (Zhao 
et al., 2007) suggesting that RNA Pol II may be paused at Polycomb target genes.  This led to 
the hypothesis that Polycomb target genes can recruit RNA Pol II to their promoters and 
engage in transcriptional initiation, but prior to elongation, the polymerase encounters a 
block.  Indeed, a recent study identified a class of short RNAs transcribed from Polycomb 
target genes that could recruit PRC2 to mediate repression in cis (Kanhere et al., 2010).  
Additional work will be required to confirm these findings and determine how PRC2 and 
H3K27 tri-methylation function to block the transition from transcriptional initiation to 
elongation. 
  
RECRUITMENT OF PRC2 TO GENOMIC TARGETS 
One persistent question in the field of Polycomb mediated gene silencing is how 
Polycomb complexes are recruited to chromatin.  Although it is widely believed that PRC1 
recruitment depends on the presence of tri-methylated H3K27 marks placed by PRC2, it is 
unclear how PRC2 itself is targeted to chromatin.  Efforts to reveal how Polycomb 
complexes are mobilized to target genes were initially focused on defining DNA sequence 
elements and identifying factors that can bind to DNA.  This mechanism of recruitment 
proved to be the case for Drosophila where DNA sequence elements called Polycomb 
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response elements (PREs) were identified in HOX genes based on their ability to confer 
Polycomb repression of reporter genes (Muller and Kassis, 2006; Ringrose and Paro, 2007). 
Genetic experiments allowed for the identification of several DNA binding proteins 
that contribute to Polycomb repression.  One key factor that binds to some PREs is the zinc 
finger protein, PHO (Pleiohomeotic) and the related protein, PHOL (PHO-like) which are 
required for PRE-mediated transgene silencing (Brown et al., 2003; Brown et al., 1998; 
Fritsch et al., 1999; Mihaly et al., 1998; Shimell et al., 2000).  PHO functions as a stable 
heterodimer by interacting with the Polycomb protein, SFMBT (Scm-like with four MBT 
domain-containing protein 1) (Klymenko et al., 2006; Oktaba et al., 2008).  Consistent with a 
function for PHO at endogenous targets, PHO mutants exhibit defects in HOX gene silencing 
(Choi et al., 2000).  ChIP experiments demonstrate that disruption of PHO results in loss of 
PRC1 and PRC2 at HOX PREs (Wang et al., 2004b).  Furthermore, mutation of PREs at 
PHO binding sites leads to loss of PRC1 and disrupted silencing (Klymenko et al., 2006).   
Although many studies have illustrated that binding of PHO to PREs is a key event in 
mediating Polycomb repression, PHO alone is not sufficient to confer silencing (Brown et al., 
2003; Dejardin et al., 2005; Fritsch et al., 1999; Shimell et al., 2000).  Genome-wide 
mapping revealed that a significant number Polycomb targets containing PRC1 and PRC2 do 
not contain PHO (Kwong et al., 2008; Oktaba et al., 2008; Schuettengruber et al., 2009).  
Indeed, many other DNA binding proteins can bind to PREs and include: GAF (GAGA 
factor), Pipsqueak, Zeste, DSP1 (Dorsal switch protein 1), and Grainyhead (reviewed in 
(Muller and Kassis, 2006; Ringrose and Paro, 2007; Schuettengruber et al., 2007).  However, 
it appears that these proteins play a smaller role in Polycomb recruitment as they exhibit 
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minor overlap with PRC1 and PRC2 binding sites in the genome (Oktaba et al., 2008; 
Schuettengruber et al., 2009).   
Altogether, genome-wide studies have validated a central role for PHO whereas other 
DNA binding proteins appear to play a limited role.  Given that any one of these factors only 
partially overlaps with Polycomb target genes, it is likely that the recruitment of Polycomb 
complexes is facilitated by a combination of DNA binding proteins.  Drosophila PREs 
appear to be quite complex as there is no single consensus sequence that can confer PRE 
function.  Instead, these “elements” represent a collection of transcription factor binding sites 
as they vary in length but are often in the range of several hundred bases.  In addition to the 
factors listed above, the list of Polycomb complex recruiters is likely to expand.  Through the 
use of multiple transcription factors, regulation of gene expression can occur with greater 
flexibility.  A complete molecular description of PREs is currently lacking although it is very 
likely that multiple subclasses of PREs consisting of different transcription factor binding 
sites exist. 
Although the mechanism of Polycomb recruitment is not entirely clear in Drosophila, 
it is even more poorly understood in mammals.  It is known that PRC2 complexes target 
sequences highly enriched in CG, most of which are classified as CpG islands, but these 
sequences alone do not confer a consensus response element (Ku et al., 2008).  A mammalian 
PRE was recently identified in mammals, and it was suggested that YY1, the mammalian 
homolog of PHO, plays an important role in the recruitment of Polycomb complexes (Sing et 
al., 2009; Woo et al., 2010).  However, genome wide analysis did not demonstrate a clear 
overlap between YY1 and Polycomb target genes (Squazzo et al., 2006; Xi et al., 2007).  As 
discussed earlier, the Jumonji domain containing protein JARID2 has been implicated in the 
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recruitment of PRC2 to target genes (Landeira et al., 2010; Li et al., 2010; Pasini et al., 2010; 
Peng et al., 2009) but genetic evidence as well as the observation that H3K27 tri-methylation 
is only modestly affected when JARID2 is depleted makes this mode of recruitment less 
attractive.  Hence, there is little compelling evidence thus far for the participation of 
transcription factors in the recruitment of PRC2 in mammals.  Furthermore, it is highly 
unlikely that only a few transcription factors are involved in the recruitment and 
displacement of Polycomb complexes given the diversity of target genes in mammals that 
must be regulated in a cell type specific manner. 
Emerging evidence suggests that long non-coding RNAs (lncRNAs) are important 
participants in recruiting PRC2 complexes to their target genes.  Members of this class of 
RNAs are generally over 200 nucleotides in length and account for the vast majority of 
transcription that occurs in the cell (Kapranov et al., 2007).  Contrary to the notion that 
lncRNAs represent transcriptional noise, recent studies have ascribed functional roles for 
lncRNAs including their involvement in the recruitment of PRC2 to target genes.  LncRNAs 
provide an attractive mechanism for PRC2 recruitment due to their proposed abilities to bind 
to genomic DNA in a sequence-specific manner. 
One well characterized lncRNA involved in PRC2 recruitment is XIST (X inactive-
specific transcript).  In mammals, X-chromosome inactivation is initiated by the transcription 
of this 17 kilobase lncRNA which coats the X-chromosome in cis and commences changes in 
the chromatin structure characterized by progressive heterochromatinization (Payer and Lee, 
2008).  This includes XIST-dependent recruitment of the PRC2 complex to the inactive X-
chromosome which becomes tri-methylated at H3K27 (Plath et al., 2003).  Within the XIST 
molecule, a 28 base pair repeat element called repA, which is required for silencing of the 
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inactive X-chromosome, forms two stem loop structures that can bind to PRC2 in vitro 
(Maenner et al., 2010; Zhao et al., 2008). 
Similar to XIST, the lncRNA KCNQ1OT1 (Kcnq1 overlapping transcript 1) is 
transcribed from a locus encompassing ten paternally imprinted genes in a 1 megabase region 
(Wu and Bernstein, 2008).  This lncRNA interacts with PRC2 and is required for H3K27 tri-
methylation and silencing of the locus (Pandey et al., 2008; Terranova et al., 2008).  In 
contrast to XIST and KCNQ1OT1 which function in cis, lncRNAs can also recruit PRC2 to 
facilitate transcriptional repression in trans.  The 2.2 kilobase lncRNA, HOTAIR (HOX 
antisense intergenic RNA) is expressed from the HOXC locus and is essential for the 
repression of a 40 kilobase region of the HOXD locus (Rinn et al., 2007).  A direct 
interaction with PRC2 was established and HOTAIR-depleted cells exhibit a loss of H3K27 
tri-methylation at the HOXD locus.  It is likely that many other lncRNAs also function in 
trans as in situ hybridization of HOTAIR and four other lncRNAs revealed multiple speckle 
patterning in the cell nucleus (Khalil et al., 2009) suggesting that these lncRNAs may recruit 
PRC2 to various regions of the genome.  Given that one fifth of all lncRNAs identified have 
been reported to be associated with PRC2 (Khalil et al., 2009), it is believed the use of 
lncRNAs constitutes a widespread mechanism for the recruitment of PRC2.   
 
ES CELL PLURIPOTENCY, SELF-RENEWAL, AND DIFFERENTIATION 
 ES cells are stem cells derived by the inner cell mass of the blastocyst during 
embryonic development.  Two distinguishing properties define ES cells which are their 
pluripotency (or their potential to give rise to all cell types) and their capacity to self-renew 
(or replicate indefinitely).  Polycomb proteins are highly expressed in ES cells and function 
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by maintaining the repression of developmental regulators (Boyer et al., 2006).  During 
differentiation, commitment to a cell lineage is executed in part by the activation of specific 
transcriptional programs and coincides with reduced expression of Polycomb proteins.  In 
terminally differentiated cells, expression of Polycomb proteins is very low.   
Loss of ES cell pluripotency during differentiation may be caused by (1) expression 
of developmental regulators that promote differentiation or (2) repression of factors required 
for pluripotency.  In line with the first hypothesis, the fact that PRC2 stably represses 
numerous developmental regulators in ES cells initially led to the suggestion that PRC2 is 
required for the maintenance of ES cells.  However, mouse ES cells lacking components of 
PRC2 remain in an ES cell-like state (Chamberlain et al., 2008; Pasini et al., 2007; Shen et 
al., 2008).  Although loss of PRC2 does not appear to affect the maintenance of ES cells, 
defects in differentiation are very apparent in these cells.  EZH2- and EED-null ES cells 
exhibit a severe defect in commitment to the mesoendodermal lineage (Chamberlain et al., 
2008; Shen et al., 2008) while SUZ12-deficient ES cells fail to produce a proper endodermal 
layer (Pasini et al., 2007).  In these cells, pluripotency factors including NANOG and OCT4 
are insufficiently silenced suggesting that their sustained expression overrides the aberrant 
expression of developmental regulators.  Collectively, these observations support the second 
hypothesis where loss of the ES cell state requires the repression of pluripotency factors. 
 
EZH2 AND HUMAN CANCERS  
Upregulation of EZH2 is observed in a broad range of human cancers including 
prostate cancer (Bachmann et al., 2006; Hoffmann et al., 2007; Varambally et al., 2002), 
breast cancer (Bachmann et al., 2006; Kleer et al., 2003; Pietersen et al., 2008), and 
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melanoma (Bachmann et al., 2006).  Its overexpression promotes neoplastic transformation 
of prostate and breast epithelial cells (Karanikolas et al., 2009; Kleer et al., 2003) and the 
highest levels of EZH2 correlates with the worst prognosis for the patient (Varambally et al., 
2002).  Hence, EZH2 has been considered to be a marker for the aggressive stages of prostate 
and breast malignancies (Kleer et al., 2003; Varambally et al., 2002).  These observations 
suggest an important role for EZH2 in the progression of human cancers and have been the 
rationale behind the development of therapeutic drugs that target EZH2 and other histone 
methyltransferases (Copeland et al., 2009). 
 Expression of EZH2 is regulated by the pRB-E2F (Bracken et al., 2003), a pathway 
that regulates genes whose products control cell cycle progression.  Both mRNA and protein 
levels of EZH2 accumlate at early S phase (Bracken et al., 2003) presumably so that tri-
methylated H3K27 marks are transmitted to newly synthesized chromatin (Hansen et al., 
2008).  EZH2 is essential for proliferation of both transformed and non-transformed cells 
(Bracken et al., 2003) as its depletion not only confers a proliferative disadvantage, but also 
leads to an accumulation of cells in the G2/M phase (Varambally et al., 2002).  Conversely, 
primary cells ectopically expressing Ezh2 proliferate faster (Bracken et al., 2003) 
characteristic of other oncogenic genes.   
 Proliferating cells must inhibit cellular senescence pathways in order to maintain their 
proliferative potential.  One mechanism by which EZH2 promotes evasion of senescence is 
by targeting and transcriptionally silencing the CDKN2A locus (cyclin-dependent kinase 
inhibitor 2A) which encodes for the tumor suppressor proteins, p16INK4A and p14ARF.  A 
number of studies have demonstrated that repression of this locus requires both PRC2 and 
H3K27 tri-methylation (Agherbi et al., 2009; Bracken et al., 2007; Kotake et al., 2007).  
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Furthermore, EZH2 is downregulated in senescing populations of cells and is concomitant 
with decreased levels of tri-methylated H3K27 and activation of the tumor suppressor genes.  
Consistent with this observation, Ezh2 expression is very low in terminally differentiated 
somatic cells compared to ES cells (Margueron et al., 2008; Shen et al., 2008).  Hence, it is 
believed that the oncogenic potential of EZH2 stems from its role in the repression of tumor 
suppressor genes.  
Given that EZH2 participates in a network of pathways that are involved in cell cycle 
regulation, it is not surprising that overexpression of EZH2 correlates with oncogenesis.  
Like EZH2, many Polycomb proteins including other components of the PRC2 complex have 
also been implicated in cell cycle regulation and are aberrant in a variety of human cancers 
(Bracken and Helin, 2009).   However, it remains unclear to what extent Polycomb proteins 
contribute to oncogenesis.  Many tumors have reactivated the expression of stem cell-
associated genes such as HOX genes (Shah and Sukumar, 2010) which are the best 
characterized targets of Polycomb proteins, but whether this is the cause or consequence of 
transformation remains to be determined.  Nevertheless, these observations illustrate the 
importance of proper regulation of EZH2 function.   
 
RESEARCH SUMMARY 
 The work described in this dissertation encompasses two major research projects that 
were conducted during my graduate training, both of which pertain to the molecular function 
and regulation of EZH2.  The first project concerns the demonstration that lncRNAs are 
novel targets of EZH2.  Although lncRNAs were originally considered to be transcriptional 
“noise”, they exhibit cell type specific expression patterns (Dinger et al., 2008; Mercer et al., 
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2008; Ravasi et al., 2006) which suggests they may actually be functional.  In addition, 
genome wide maps of histone modifications revealed many regions containing active marks 
that could not be attributed to protein-coding genes (Guttman et al., 2009).  These 
observations suggest that like protein-coding genes, lncRNAs are epigenetically regulated. 
However, this hypothesis has never been directly tested and was the basis for the work 
performed and described in Chapter 2.   
With regards to my second project, it was very apparent at the start of my graduate 
training that the function of EZH2 had to be properly regulated in the cell, but molecular 
mechanisms of EZH2 regulation were poorly understood.  Therefore, I set out to investigate 
this question as part of my dissertation work.  At that point in time, one study had just 
reported that EZH2 function could be inhibited via phosphorylation which was mediated by 
the kinase Akt (Cha et al., 2005).  Given that phosphorylation is a well-studied post-
translational modification that can have a tremendous impact on protein function, I decided 
to identify and characterize novel EZH2 phosphorylation sites.   
In the work described in Chapter 3, I demonstrate that additional EZH2 
phosphorylation sites exist particularly sites of threonine phosphorylation.  Furthermore, I 
provide evidence that phosphorylation of the PRC2 complex can affect its HMT activity.  
These findings set the stage for work described in Chapter 4 where I characterize the 
regulation and function of two novel EZH2 phosphorylation sites, T345 and T487.  These 
modifications are mediated by the cyclin dependent kinase, CDK1 and contribute to the 
instability of EZH2.  This finding is particularly interesting due to the significance of both 
EZH2 and CDK1 in cell proliferation and human cancer.   
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 As a whole, my dissertation highlights the use of diverse analytical methods 
commonly used to address questions in the field of epigenetics.  These methods include 
bioinformatic analysis, expression microarrays, genetic manipulation, biochemical analysis, 
and cell biology techniques.  The use of these tools to study the function and regulation of 
EZH2 have revealed novel aspects in the field of Polycomb-mediated silencing.   
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Figure 1.1 Mechanisms of DNA methylation and demethylation.   
During early development, methylation patterns are initially established by de novo DNA 
methyltransferases, Dnmt3a and Dnmt3b.   When DNA replication and cell division occur, 
these marks are maintained in daughter cells by the maintenance methyltransferase, Dnmt1, 
which has a preference for hemi-methylated DNA.  If Dnmt1 is inhibited or absent when the 
cell divides, the newly synthesized strand of DNA will not be methylated and successive 
rounds of cell division will result in passive demethylation.  On the other hand, active 
demethylation can occur through enzymatic replacement of 5-methylcytosine with cytosine. 
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Figure 1.2 Chemical structures of various methylated arginines and lysines. 
 (A) Arginines can be mono-methylated, symmetrically di-methylated, or asymmetrically di-
methylated.  (B) Lysines can be mono-methylated, di-methylated, or tri-methylated.  Each 
methylation state is catalyzed by methyltransferases (MTase). 
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Figure 1.3 Biochemical composition of the PRC1 complex in flies and humans. 
The PRC1 complex has the capacity to mono-ubiquitinate the N-terminal tail of histone H3 at 
K119.  This complex is highly conserved in (A) flies and (B) humans and consists of 
SCE/dRING, PSC, PC, and PH in flies and RING1B, BMI1, PC1, and PH1 in mammals.  
The RING domain-containing proteins, SCE/dRING and RING1B confer E3 ubiquitin ligase 
activity for the complex.  Homologues are represented by the same coloring scheme.  Solid 
arrows point to orthologs that can also participate in the complex.  
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Figure 1.4 Biochemical composition of the PRC2 complex in flies and humans. 
The PRC2 complex has the capacity to di- and tri-methylate the N-terminal tail of histone H3 
at K27.  This complex is highly conserved in (A) flies and (B) humans.  The minimal core 
proteins required for histone methyltransferase activity are E(Z), ESC, and SU(Z)12 in flies 
and EZH2, EED, and SUZ12 in mammals where E(Z) and EZH2 contain a SET domain that 
confers histone methyltransferase activity.  NURF55 and RBAP48 significantly stimulate the 
enzymatic activity of the complex.  Homologues are represented by the same coloring 
scheme.  Solid arrows point to orthologs that can also participate in the complex.  Dotted 
arrows represent proteins that are sometimes observed as stable components of PRC2 
complexes.   
 
 
 
 
 32 
Figure 1.5 Resolution of bivalent genes during ES cell differentiation. 
In embryonic stem (ES) cells, promoters of genes encoding for developmental regulators are 
maintained in a “poised” state through the presence of two opposing epigenetic marks, 
H3K4me3 and H3K27me3 also known as bivalent domains.  These genes may be 
sporadically transcribed, but are generally considered to be in a repressed state.  Upon ES 
cell differentiation, most bivalent genes are resolved and this occurs through the loss of one 
of the two opposing marks.  Activation of genes is executed by removing the repressive 
H3K27me3 mark while repression is mediated by loss of the active H3K4me3 mark.  
Enforced repression can be facilitated through the addition of other repressive marks such as 
H3K9me3 and DNA methylation.  Some bivalent genes are not resolved upon ES cell 
differentiation and these constitute a small minority of genes in somatic cells. 
 
 
 
 33 
Figure 1.6 Coordinated actions of the Polycomb repressive complexes. 
Polycomb-mediated repression of target genes is mediated by the cooperative activities of the 
PRC2 and PRC1 complex.  The first step of this process involves the recruitment of PRC2 to 
target promoters which become tri-methylated at H3K27.  This epigenetic mark can serve as 
a binding site for the Polycomb protein, PC which participates in the PRC1 complex.  Thus, 
PRC1 is brought to these loci and subsequently mono-ubiquitinates H3K119, a mark that is 
associated with transcriptional repression. 
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Table 1.1 Core components of Polycomb complexes in flies and humans 
 
Complex Fly Human Biochemical Role 
Polycomb (Pc) 
PC1 (CBX2) 
PC2 (CBX4) 
PC3 (CBX6-8) 
Binds tri-methylated H3K27 
Polyhomeotic (Ph) PH1 PH2 Required for silencing 
Posterior sex combs (Psc) 
BMI1 
MEL18 (PCGF2) 
NSPC1 (PCGF1) 
Stimulates E3 ubiquitin ligase 
activity 
 
PRC1 
Sex combs extra (Sce, 
dRING1) 
RING1 (RING1A) 
RING2 (RING1B) 
E3 ubiquitin ligase activity for 
H2A K119 
Enhancer of zeste (E(z)) EZH1 EZH2 
H3K27 methyltransferase 
activity 
Suppressor of zeste 12 
(Su(z)12) SUZ12 
Stimulates H3K27 
methyltransferase activity 
Extra sex combs (Esc) EED Stimulates H3K27 methyltransferase activity 
 
PRC2 
Nucleosome remodeling 
factor 55 (Nurf55) 
RBAP46 (RBBP7) 
RBAP48 (RBBP4) Nucleosome binding 
Binds 
PRC2 Polycomb-like (Pcl) 
PCL1 (PHF1) 
PCL2 (MTF2) 
PCL3 (PHF19) 
Stimulates H3K27 
methyltransferase activity  
Recruits PRC2 
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ABSTRACT 
 
Once thought to be transcriptional noise, long non-coding RNAs (lncRNAs) have 
recently been demonstrated to be functional molecules.  Cell-type specific expression 
patterns of lncRNAs suggest that their transcription may be regulated epigenetically.  Using a 
custom-designed microarray, here we examine the expression profile of lncRNAs in 
embryonic stem (ES) cells, lineage-restricted neuronal progenitor cells (NPC), and terminally 
differentiated fibroblasts. In addition, we also analyze the relationship between their 
expression and their promoter H3K4 and H3K27 methylation patterns. We find that 
numerous lncRNAs in these cell types undergo changes in the levels of expression and 
promoter H3K4me3 and H3K27me3.  Interestingly, lncRNAs that are expressed at lower 
levels in ES cells exhibit higher levels of H3K27me3 at their promoters. Consistent with this 
result, knockdown of the H3K27me3 methyltransferase EZH2 results in derepression of these 
lncRNAs in ES cells.  Thus, our results establish a role for EZH2-mediated H3K27 
methylation in lncRNA silencing in ES cells and reveal that lncRNAs are subject to 
epigenetic regulation in a similar manner to that of protein coding genes. 
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INTRODUCTION 
 
Recent studies have revealed that the mammalian “transcriptome” is much more 
substantial and complex than originally believed.  The ENCODE project estimates that over 
90% of all nucleotides within the human genome can be transcribed (Birney et al., 2007).  
Although transcription appears to be quite pervasive, only 15% of the genome experiences 
stable transcription in human cell lines (Cheng et al., 2005).  Nevertheless, protein coding 
genes account for just 1-2% of the genome (Consortium, 2004) suggesting that cells dedicate 
a considerable amount of energy to produce transcriptional “dark matter” (Johnson et al., 
2005). 
Although small RNAs (microRNAs, PIWI-associated RNAs, and small interfering 
RNAs) and housekeeping RNAs (transfer RNAs and ribosomal RNAs) account for some 
non-protein coding transcripts, the vast majority are long non-coding RNAs (lncRNAs) that 
are greater than 200 nucleotides in length (Kapranov et al., 2007a).  Although lncRNAs were 
once considered to be transcriptional noise, several features suggest that lncRNAs may play 
important roles in various processes. These features include: 1) cell-type specific expression 
patterns (Dinger et al., 2008; Mercer et al., 2008; Ravasi et al., 2006); 2) distinct subcellular 
localizations (Mercer et al., 2008); 3) link to various diseases (Ponting et al., 2009); and 4) 
evolutionary selection of the lncRNA sequence (Guttman et al., 2009; Ponjavic et al., 2007).  
Indeed, recent studies have uncovered functional roles for lncRNAs in diverse biological 
processes including X-inactivation, imprinting, Hox gene regulation, and the development of 
certain diseases (Nagano et al., 2008; Ponting et al., 2009; Rinn et al., 2007; Wilusz et al., 
2009; Zhao et al., 2008). 
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Epigenetic modifications, including DNA methylation, histone modifications, and 
chromatin remodeling are believed to contribute to cell-type specific expression patterns of 
protein-coding genes (Cedar and Bergman, 2009; Martin and Zhang, 2005).  Interestingly, a 
previous study has identified many genomic regions that contain the active histone 
modification marks H3K4me3 and H3K36me3, which could not be attributed to protein-
coding genes (Guttman et al., 2009).  While this suggests that lncRNAs may be regulated 
epigenetically in a similar way to that of protein coding genes, this has not been tested 
directly. 
  To begin to understand the mechanism by which lncRNAs exhibit cell-type specific 
expression, we compared the expression profiles of lncRNAs in mouse ES cells, neuronal 
progenitors (NPCs), and terminally differentiated fibroblasts and analyzed the relationship 
between their expression and their promoter H3K4me3 and H3K27me3 levels. We found that 
these histone modifications undergo dynamic changes in a cell-type specific manner.  In 
addition, we found that EZH2-mediated H3K27 methylation plays an important role in 
silencing lncRNAs in ES cells. Our results suggest that lncRNAs are epigenetically regulated 
in a similar manner to that of protein coding genes.    
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RESULTS 
 
Expression profiling of lncRNAs in ES cells, NPCs, and fibroblasts 
Of the 34,030 lncRNAs annotated in the Fantom3 database, 32,213 (95%) were 
mapped to the UCSC mm8 assembly of the mouse genome.  To determine whether lncRNAs 
are differentially expressed in cells at different differentiation stages, we analyzed their 
expression in mouse ES cells, lineage-restricted neuroprogenitors (NPCs), and terminally 
differentiated fibroblasts using a custom-designed microarray containing oligonucleotide 
probes targeting these lncRNAs. Given that multiple transcriptional units can coexist within 
the same genomic space (Carninci et al., 2005; Carninci et al., 2006; Ge et al., 2006; 
Kapranov et al., 2007b; Katayama et al., 2005), lncRNAs may be regulated indirectly by 
their location within the same transcriptional unit of a protein-coding gene. To simplify the 
analysis, we focused on the subset of lncRNAs that did not overlap with the promoter 
(defined as -1kb to +1kb surrounding the transcription start site) or the coding region of 
annotated genes.  We found that the majority (65%, n=20949) of mapped lncRNAs annotated 
in the Fantom3 database overlapped with coding regions of genes annotated in the RefSeq 
database.  A small fraction (1%, n=327) overlapped with gene promoters.  The remaining 
lncRNAs (34%, n=10937) showed no overlap with annotated promoters or coding regions 
(Figure 2.1A). These lncRNAs were used for all subsequent analyses.  
We found that 3270 (10.2%) unique lncRNAs exhibit at least a two-fold change when 
compared from one cell type to another (Figure 2.1B).  LncRNAs that exhibited at least a 
two-fold change in ES cells compared to both NPCs and fibroblasts were randomly selected 
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and confirmed by quantitative PCR analysis (Figure 2.1C).  These studies indicate that at 
least a subset of lncRNAs exhibit cell type-specific expression.   
 
H3K4me3 and H3K27me3 distribution in lncRNA promoters in ES, NPC, and 
fibroblasts 
Given that epigenetic mechanisms contribute to cell-type specific expression of 
protein coding genes, we asked whether lncRNAs are epigenetically regulated.  The 
Trithorax and Polycomb group of proteins are key developmental players responsible for 
lineage-specific gene expression (Schuettengruber et al., 2007).  Some of these proteins 
participate in multi-protein complexes that are responsible for the tri-methylation of lysine 4 
and 27 of histone H3 (H3K4me3 and H3K27me3) with H3K4me3 and H3K27me3 
correlating with transcriptional activation and repression, respectively (Martin and Zhang, 
2005).  Specific genomic regions in ES cells are marked with both H3K4me3 and 
H3K27me3 and are termed “bivalent” domains, which are transcriptionally inactive regions 
that are poised for transcriptional activation (Bernstein et al., 2006). 
Taking advantage of previously published genome-wide location data for H3K4me3 
and H3K27me3 (Mikkelsen et al., 2007), we examined these two histone methylation marks 
at the promoters of lncRNAs in mouse ES cells, NPCs, and fibroblasts (Figure 2.2A).  We 
found a small group of unique lncRNAs (17%) that contain these modifications.  In ES cells, 
roughly 80% of all H3K27me3 positive lncRNA promoters also contain H3K4me3, which is 
similar to previous reports on protein coding genes (Bernstein et al., 2006).  In contrast to 
H3K27me3, less than a quarter of all H3K4me3 positive promoters are bivalent suggesting 
that most H3K4me3 positive lncRNAs may have housekeeping functions or are important for 
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ES cell identity.  Overall, ES cells contained more bivalent lncRNA promoters when 
compared to NPCs and fibroblasts.  In addition, H3K27me3 alone is notably enriched in 
fibroblasts compared to ES cells and NPCs indicating that this subset of lncRNAs may have 
to be silenced in terminally differentiated cells. 
We then asked whether lncRNAs containing these modifications retain the same 
modification or if they undergo epigenetic changes when ES cells become lineage-restricted 
(NPC) or terminally differentiated (fibroblasts). Unlike those lacking modifications, many 
lncRNAs that possess H3K4me3, H3K27me3, or both do undergo dynamic changes (Figure 
2.2B).  Interestingly, while more than half of lncRNAs possessing H3K4me3 in ES cells 
retain this mark, the majority of bivalent lncRNAs in ES cells commit to either the active or 
repressive mark in NPCs and fibroblasts.  This suggests that the lncRNAs retaining 
H3K4me3 may have housekeeping functions, while those with the bivalent mark in ES cells, 
but commit to the active or repressive mark in NPCs or fibroblasts may have important roles 
in cell lineage commitment. On the other hand, the group of lncRNAs that loses the 
H3K4me3 mark in NPCs and fibroblasts may be interesting for future studies as these may 
be important for ES cell identity.  It is interesting to note that most lncRNAs containing only 
H3K27me3 in ES cells appear to lose this modification in NPCs and fibroblasts, particularly 
in NPCs (Figure 2.2B). 
 
Promoter H3K4me3 and H3K27me3 correlate with lncRNA transcription levels 
We next set out to examine whether changes in H3K4 and H3K27 methylation of 
lncRNA promoters correlate with expression of lncRNAs.  To this end, lncRNAs were 
categorized into two groups based on their expression levels in ES cells compared to both 
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NPCs and fibroblasts (at least a 2-fold change in ES versus NPCs/fibroblasts).  The average 
tag density for H3K4me3 and H3K27me3 was examined over a region +/- 5kb from the 
transcription start site using previously published data (Mikkelsen et al., 2007). Similar to 
previous reports on protein coding genes, levels of H3K4me3 peak at transcription start sites 
(TSS) and are independent of expression status (Figure 2.3A).  However, lncRNAs that were 
expressed higher in ES cells compared to NPCs/fibroblasts tended to have slightly higher 
levels of H3K4me3.  On the other hand, lncRNAs that were expressed at lower levels in ES 
cells exhibited a broad peak of H3K27me3 that sharply dropped after the transcription start 
site (Figure 2.3B).  Levels of H3K27me3 remained consistently low in the same region when 
the opposite group was examined. 
  As mentioned above, previous studies of protein coding genes in ES cells suggest that 
gene promoters marked by bivalent domains are thought to be poised for activation or 
repression upon differentiation (Bernstein et al., 2006).  To determine whether the same trend 
holds true for lncRNAs, we categorized lncRNAs that were bivalent in ES cells based on 
their modification state in fibroblast cells and examined their expression change upon 
differentiation.  On average, bivalent lncRNAs that become H3K4me3 in fibroblasts are 
expressed significantly higher in fibroblasts compared to ES cells, while those that become 
H3K27me3 are expressed significantly lower (Figure 2.3C).  Collectively, the above results 
demonstrate that H3K4me3 and H3K27me3 can be correlated with the activation and 
repression of lncRNAs, respectively.  Therefore, the relationship between transcription levels 
and promoter H3K4me3 and H3K27me3 levels previously discovered for protein coding 
genes holds true for lncRNAs. 
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EZH2-mediated H3K27 methylation represses lncRNAs in ES cells 
We next asked whether the presence H3K27me3 at the promoter affects expression of 
lncRNAs in ES cells.  To this end, we attempted to manipulate levels of H3K27me3 by 
knocking down EZH2, the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2) 
(Cao et al., 2002).  We generated lentiviruses expressing two independent shRNAs targeting 
EZH2, which we used for transduction of ES cells.  Following puromycin selection, 
knockdown efficiency was confirmed by RT-qPCR (Figure 2.4A). Consistent with down-
regulation of EZH2, global levels of H3K27me3 were dramatically reduced (Figure 2.4B). 
We analyzed the lncRNA expression profile in EZH2 KD ES cells using the custom-
designed microarray described earlier and found that both knockdowns correlated well with 
each other (Pcc = 0.935).  To determine whether H3K27me3 plays a role in silencing 
lncRNAs in ES cells, we grouped lncRNAs based on the presence of H3K4me3 or 
H3K27me3 at their promoter and examined their expression change upon EZH2 knockdown 
(Figure 2.4C).  Not surprisingly, lncRNAs marked by H3K4me3 exhibited no significant 
changes in expression compared to all lncRNAs.  On the other hand, we found that lncRNAs 
containing H3K27me3 tend to be expressed at a higher level upon EZH2 knockdown when 
compared to those containing H3K4me3 (p = 1.415 x 10-10) or all lncRNAs (p = 9.64 x 10-9) 
indicating that EZH2-mediated H3K27 methylation contributes to the repression of a subset 
of lncRNAs in ES cells. 
To further analyze the effect of EZH2 knockdown on lncRNA expression, we 
examined the microarray data and found 163 lncRNAs that were at least 2-fold upregulated 
in both knockdowns of EZH2.  Of these, 19 were also marked with H3K27me3 in ES cells.  
From this group, we randomly selected 6 lncRNAs and confirmed that their expression was 
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de-repressed upon EZH2 knockdown by RT-qPCR (Figure 2.4D).  The effect of EZH2 on 
these lncRNAs appears to be direct as analysis of previously published genome-wide 
mapping data (Ku et al., 2008) indicated that the promoters of these lncRNAs are not only 
bound by EZH2 but also by Suz12, another component of the PRC2 complex (Cao et al., 
2002).  
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DISCUSSION 
 
In summary, our study examined the lncRNA expression profiles in ES, NPC, and 
fibroblasts and analyzed their relationship with their promoter H3K4me3 and H3K27me3 
levels. Our results indicate that similar to protein coding genes, H3K4me3 and H3K27me3 
are generally correlated to lncRNA activation and repression, respectively. In addition, 
through shRNA-mediated knockdown of EZH2 in ES cells, we demonstrate that EZH2-
mediated H3K27 methylation also functions to repress the expression of lncRNAs, thus 
extending the observations from protein coding genes to lncRNAs. 
Our finding that the Polycomb group of proteins regulates lncRNAs in addition to 
protein coding genes prompted us to investigate whether transcription factors are also 
involved in regulating lncRNAs.  Taking advantage of previously published genome wide 
localization maps of transcription factors involved in ES cell biology (Chen et al., 2008), we 
examined the promoter regions of lncRNAs for the presence of transcription factors.  Our 
analysis indicates that 30% (3232 out of 10937) of the lncRNAs in our dataset contain at 
least one transcription factor bound to its promoter (data not shown).  Furthermore, the 
promoter regions of almost 300 lncRNAs contain at least 3 of the 4 core transcription factors 
important for ES cell maintenance (Nanog, Oct4, Sox2, and Klf4) (data not shown).  These 
results suggest that transcription factors may play a role in regulating lncRNAs.  It is also 
possible that other regulatory mechanisms employed by protein coding genes may apply to 
lncRNAs. 
Several lncRNAs including Xist, HOTAIR, and AIR have recently been demonstrated 
to be functional molecules important for specific biological processes (Nagano et al., 2008; 
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Rinn et al., 2007; Zhao et al., 2008).  Given that over 30,000 lncRNAs have been annotated 
in the FANTOM database, it is very likely that many more functional lncRNAs will be 
identified.  In support of this prediction, we find that a subset of lncRNAs are differentially 
expressed and marked with different histone modifications suggesting that these molecules 
play specific roles in different cell types.  However, characterizing their biochemical and 
biological function is no trivial matter.  Based on the few number of characterized lncRNAs, 
it is clear that lncRNAs can participate in various biological processes and function through 
diverse mechanisms (Ponting et al., 2009; Wilusz et al., 2009) thus making it difficult to 
predict their mechanism of action. 
Despite these challenges, our demonstration that lncRNAs are regulated in a manner 
similar to that of protein coding genes allows for identification of functional lncRNAs 
through a candidate-based approach by analyzing expression data as well as the presence or 
absence of specific histone modifications.  Because we find that a subset of lncRNAs are 
developmentally regulated, it will be of great interest to determine if lncRNAs play a crucial 
role in ES cell biology.  Our analysis indicates that there are 13 lncRNAs that contain 
H3K4me3 (and no H3K27me3) in ES cells in addition to H3K27me3 (and no H3K4me3) in 
either NPCs or fibroblasts.  Of these, 5 lncRNAs are expressed at least 2 fold higher in ES 
cells compared to NPCs or fibroblasts.  These lncRNAs can be experimentally tested as 
candidates important for ES cell biology using a knockdown approach.  A similar approach 
can be used to identify candidate lncRNAs that may be important for ES cell differentiation. 
The production of diverse cell types in an organism has traditionally been attributed 
to differential gene expression that is controlled in part through epigenetic mechanisms such 
as histone modifications.  However, emerging evidence demonstrating the differential 
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expression of lncRNAs has indicated that lncRNAs may also contribute to this process.  
While many challenges remain with regards to determining the significance of these 
molecules, our work provides a resource for the scientific community to identify candidate 
lncRNAs that are important in ES cell biology.  While only a fraction of annotated lncRNAs 
have currently been characterized, future work will undoubtedly uncover a larger biological 
role for lncRNAs than originally anticipated.    
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EXPERIMENTAL PROCEDURES 
 
lncRNA definitions and analysis:  The positions of lncRNAs from the Fantom3 database 
were extracted from http://jsm-research.imb.uq.edu.au/rnadb/ and used for all analyses in this 
work.  Promoter regions were defined as 2kb surrounding the start site (TSS) of each 
transcription unit assessed.  Overlap analysis was carried out using previously defined 
datasets:  annotated REFSEQ gene lists were procured as described in (Kallin et al., 2009), 
H3K4me3 and H3K27me3 peaks observed in ES cells, NPCs, and mouse embryonic 
fibroblasts as described in Mikkelsen et al., 2007, genome wide locations of transcription 
factors in ES cells as described in Chen et al., 2008 .  These analyses were carried out using 
the Python module FJOIN (Richardson, 2006).  Whole genome averaging of epigenetic mark 
enrichment was performed by normalizing H3K4me3 and H3K27me3 ChIP-seq reads against 
whole cell extract.  The region from -5KB to +5KB relative to the TSS was divided into 200 
bp windows and the average tag density of the subdivided promoters was computed.  Unless 
otherwise stated, only Fantom3 entries that did not overlap with annotated REFSEQ genes or 
promoters were analyzed. 
 
Microarray analysis: Total RNA was extracted from E14ps mES cells, mouse tail tip 
fibroblasts, and neurospheres, derived from E14ps mES cells using a previously published 
procedure (Ying and Smith, 2003).  RNA quality was assessed via Agilent Bioanlayzer.  
mRNA was amplified using the Low RNA Linear Amplification Kit (Agilent Technologies) 
by standard manufacturer’s protocol.  Hybridization of experimental RNA labeled with Cy5 
and Cy3 labeled Universal Reference RNA (Ambion) was carried out by standard protocol 
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on a custom-designed array manufactured by Agilent Technologies.  Briefly, three unique 
60nt probes were designed for each entry in the Fantom3 database and were synthesized 
along with lineage marker control probes on a 2x105K format array.  Upon array scanning, 
data was quality filtered, normalized by the Lowess method, and all probes corresponding to 
a given lncRNA were averaged using the UNC Microarray Database (UNCMD). Intraclass 
correlation analysis was carried out in the UNCMD.  Probe design files and microarray data 
have been submitted to the NCBI GEO database under accession number GSE22451. 
  
EZH2 knockdown and RT-qPCR: Hairpins targeting EZH2 (KD1: 5’ 
GAACTGAAACCTTAAACCA 3’; KD2: 5’ GTATGTGGGCATCGAACGA 3’) were 
cloned into a lentiviral vector under the control of the U6 promoter using previously 
published methods (He et al., 2008).  E14ps mES cells were infected with lentiviruses and 
subjected to puromycin selection. For RT-qPCR, 1µg of total RNA was subjected to reverse 
transcription using ImpromII kit (Promega).  The resulting cDNA was diluted 1:5 and 5µl of 
the resulting solution was used for Real Time PCR analysis on an Applied Biosystems 7300 
machine using SYBR GreenER (Invitrogen).  Reactions were performed in triplicate.  Gapdh 
was used as an endogenous control.  Primer sequences can be found in Table 2.1. 
 
Boxplots and Statistics: Boxplots were generated in the R package for the defined subsets of 
genes.  RT-qPCR statistics were computed using Student’s T test.  Wilcoxon signed-rank test 
(Figure 2.3C) and Student’s T test (Figure 2.4C) were employed to generate the presented p 
values. 
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Figure 2.1  LncRNAs are differentially expressed in ES cells, NPCs, and fibroblasts.  
(A) Pie chart representation of the distribution of lncRNAs in the mouse genome. 
Independent Fantom3 lncRNA entries were scanned for overlap with promoters, defined as   
-1kb to +1kb surrounding the TSS, and coding regions of annotated genes from the REFSEQ 
database.   
 
(B) Heat map presentation of the expression profile of lncRNAs in ES cells, NPCs, and 
fibroblasts. The data presented for each cell type was compared to universal reference RNA 
and was subjected to uncentered hierarchical clustering.  ES: embryonic stem cells, NPC: 
neuroprogenitors, FIB: fibroblasts.   
 
(C) RT-qPCR validation of microarray data for randomly chosen lncRNAs that exhibited at 
least 2-fold elevated transcription in ES versus both NPCs and fibroblasts. 
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Figure 2.1 (continued)   
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Figure 2.2 LncRNA promoter H3K4me3 and H3K27me3 patterns in ES cells, NPCs,  
and fibroblasts. 
 
Distribution of H3K4me3 and H3K27me3 at lncRNA promoters in ES cells, NPCs, and 
fibroblast cells for (A) all lncRNAs examined and (B) lncRNAs grouped by their epigenetic 
modification state in ES cells and then assessed for modification in both NPC and fibroblast 
cells. The presence or absence of H3K4me3 and H3K27me3 peaks was assessed within the 
promoters of lncRNAs that did not overlap with annotated REFSEQ genes (n=10937) in 
mouse ES cells, NPCs, and fibroblasts.  H3K4me3 only, blue; H3K27me3 only, red; 
H3K4me3 and H3K27me3 (bivalent), green; no H3K4me3 and no H3K27me3, purple. 
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Figure 2.3 Changes in promoter H3K4me3 and H3K27me3 levels are correlated  
with lncRNA expression. 
 
The average H3K4me3 (A) and H3K27me3 (B) tag density across the promoters of lncRNAs 
in ES cells grouped by relative expression in ES versus NPC and fibroblast.  X-axis 
represents the region spanning -5kb to +5kb away from the lncRNA transcription start site 
(TSS).  Red line indicates lncRNAs that exhibit at least 2-fold higher expression in ES cells 
relative to both NPCs and fibroblast cells, E↑N↓F↓ (n=1511).  Blue line indicates lncRNAs 
that exhibit at least 2-fold lower expression in ES cells relative to both NPCs and fibroblast 
cells, E↓N↑F↑ (n=1696).  (C) Box plot presentation of expression change (ES/FIB) in 
bivalent-marked lncRNAs in ES cells (n=321), which are further divided into three groups 
according to their promoter H3K4 and H3K27 methylation state in fibroblast cells:  
H3K4me3 and H3K27me3, Biv (n=115); H3K4me3 only, K4 (n=98); H3K27me3 only, K27 
(n=89).  Significant p values as determined by Wilcoxon signed-rank test are indicated. 
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Figure 2.3 (continued) 
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Figure 2.4 EZH2-mediated H3K27 methylation represses lncRNA transcription in  
ES cells. 
 
(A) Relative mRNA levels of EZH2 in wildtype and EZH2 knockdown ES cells as 
determined by RT-qPCR.   
 
(B) Western blot analysis of H3K27me3 levels in EZH2 knockdown ES cells.   
 
(C) Box plot presentation of expression changes (KD1/ES) in all lncRNAs (n=24357) 
compared to lncRNAs marked by promoter H3K4me3 (n=6834) or H3K27me3 (n=1294) in 
ES cells.  Significant p values were determined using the Student’s T test.  
 
(D) Relative expression of lncRNAs upon EZH2 knockdown in ES cells as determined by 
RT-qPCR.  These lncRNAs were randomly selected from the list of lncRNAs that contain 
H3K27me3 in ES cells and are at least 2-fold upregulated upon EZH2 knockdown as 
determined by microarray analysis. 
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Figure 2.4 (continued) 
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Table 2.1 Quantitative PCR primers used in the experiments described in Chapter 2. 
 
Target Forward Primer Reverse Primer 
Gapdh CATGGCCTTCCGTGTTCCTA GCCTGCTTCACCACCTTCTT 
FT326413 CCCGGCACTAGAGAAGACAG TGTGAGGATTCGTGGTTTCA 
FT331095 GAAGCCAGCAGAGGGTGTAG AGTTCCCAGAACCCATGTTG 
FT325129 GCAGATGTTTGGGCCTATGT CAGATCCACGCAGAAGTCAA 
FT35427 CCACACACGCTTCTTACCAA TAGTGTGGGGTCACAGGACA 
FT329835 CTTCATGGAGCACTGCAAAA TCCAGGCTTCACCCTAACAG 
FT325326 TTCATCAAACGATGGGAACA TTGCTTCTGGAGATGTCACG 
FT325154 CACGGAAAACTGGGTCTGAT TTTGTGTCCCCTTTCCACTC 
FT325139 ATTGTGCATCATGTGCAGGT CCCAGGTTCCATCTCCAGTA 
FT325204 TGGTCTGCACCTCATCTCTG AACCAGGTGTCCAGACCAAG 
EZH2 AACCCTGTGACCATCCACGGCAG ATCAGACGGTGCCAGCAGTAAG 
FT31040 TGAACCGAGAAAACCGAATC   TCAGGAAGCGAAAAGACGTT   
FT38422 GGATGCCTCATCTCATAGCC   TGGGGACAGGTGACACATT   
FT320624 CCCCCACTGGTTTATGTTTG   CCACCCCTAGTGACACACCT   
FT326861 GCCTTAGGATCGGAAGCTCT GATTCCCTCCATCTCACGAA   
FT38204 ACAAACACCCCTTCCTGGTA   CGGGGGCTATACTTCTCTCC 
FT319969 CCAACCTGCCAACACCTACT   CTTTCTCGCTCGCTCTCACT 
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CHAPTER 3 
 
EZH2 IS THREONINE PHOSPHORYLATED 
 78 
ABSTRACT 
 
 EZH2 (enhancer of zeste 2) is a member of the Polycomb group of proteins which are 
important developmental regulators with epigenetic functions that have been implicated in 
diverse biological processes including multi-cellular development, stem cell biology, and 
cancer development.  The importance of regulating EZH2 function is exemplified by the 
observation that it is often overexpressed in human cancers including prostate cancer where 
high levels of EZH2 is associated with the worst prognosis for the patient.  One possible 
mechanism by which EZH2 function may be regulated is through phosphorylation.  A 
previous study reported that EZH2 phosphorylation at serine 21 can be facilitated by Akt 
which inhibits its enzymatic activity.  In this chapter, I demonstrate that EZH2 is a phospho-
protein that contains other phosphorylation sites in addition to serine 21.  EZH2 contains 
sites of threonine phosphorylation in the region aa351-593 which can be regulated by protein 
phosphatase 1 and/or 2A (PP1/PP2A).  At least 5 threonines in this region (T367, T369, 
T378, T386, T388) are significant sites of phosphorylation as mutation of these threonines to 
alanines either singly or in combination decreases the total level of threonine 
phosphorylation.  Thus, these observations confirm and extend the observations that EZH2 is 
a phospho-protein and sets the stage for characterization of the aforementioned novel EZH2 
phosphorylation sites. 
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INTRODUCTION 
 
 Polycomb proteins are a group of evolutionarily conserved proteins that were 
originally discovered in Drosophila as important regulators of HOX genes, a set of 
transcription factors that specify the anterior-posterior axis and segment identity (Duncan, 
1982; Lewis, 1978; Struhl, 1981).  After HOX gene expression patterns are established in 
early development, Polycomb proteins function as a cellular memory system by stably 
repressing HOX genes outside of their expression domains and maintaining this repression 
throughout the lifespan of the organism even after numerous cell divisions.  In addition to 
HOX genes, genome-wide mapping studies revealed that Polycomb proteins also target and 
regulate many other genes mostly those encoding for transcription factors involved in diverse 
cellular functions and developmental pathways (Boyer et al., 2006; Bracken et al., 2006; Lee 
et al., 2006; Schwartz et al., 2006; Squazzo et al., 2006; Tolhuis et al., 2006).  Much attention 
has been given to Polycomb proteins given that they participate in diverse biological 
processes including multi-cellular development, X-inactivation, stem cell biology, and cancer 
development (Bracken and Helin, 2009; Mills, 2010).   
Biochemically, the mechanism by which Polycomb proteins repress target genes 
involves post-translational modifications of histone proteins.  Generally speaking, two major 
multi-protein Polycomb complexes have the capacity to modify histones, PRC1 and PRC2 
(Polycomb repressive complexes 1 and 2).  Although the protein composition of both 
complexes can vary especially in different cell types, reconstitution experiments have defined 
the core components of each complex.  In mammals, PRC1 contains RING1B (Ring finger 
protein 1B), BMI1 (B lymphoma Mo-MLV insertion region 1 homolog), various forms of PC 
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(Polycomb), and various forms of PH (Polyhomeotic) (Figure 1.3).  Importantly, RING1B 
contains E3 ubiquitin ligase activity that is stimulated by BMI to catalyze mono-
ubiquitination of H3K119 (Cao et al., 2005; Wang et al., 2004).  The core components of the 
PRC2 complex consist of EZH2 (Enhancer of zeste 2), EED (Embryonic ectoderm 
development), SUZ12 (Suppressor of zeste 12) and RBAP46/48 (Retinoblastoma associated 
protein 46 and 48) (Figure 1.4).  EZH2 possesses a SET domain and is a histone 
methyltransferase (HMT) that has the capacity to tri-methylate histone H3 at lysine 27 (Cao 
et al., 2002; Czermin et al., 2002; Kuzmichev et al., 2002; Muller et al., 2002).  Association 
with EED and SUZ12 is required for HMT activity of EZH2 (Cao and Zhang, 2004).  Given 
that the PRC1 component, PC, contains a chromodomain that can bind to tri-methylated 
H3K27 (Cao et al., 2002), it is widely believed that PRC2 functions upstream of PRC1 
(Figure 1.6). 
Recently, it has become evident that the initiation and progression of cancer is not 
only defined by mutational changes in the DNA sequence, but also by changes in the 
epigenetic status of the tumor cell.  As epigenetic regulators, Polycomb proteins and their 
functions in oncogenesis have received considerable attention.  Upregulation of EZH2 (as 
well as other members of the Polycomb group) has been reported in a broad range of human 
cancers including prostate cancer, breast cancer, and melanoma (Bachmann et al., 2006; 
Hoffmann et al., 2007; Kleer et al., 2003; Pietersen et al., 2008; Varambally et al., 2002) and 
is considered to be a marker for the aggressive stages of these cancers (Kleer et al., 2003; 
Varambally et al., 2002).  Ectopic expression of EZH2 promotes cell proliferation in primary 
cells and conversely, its depletion confers a proliferative disadvantage (Bracken et al., 2003).  
The role of EZH2 in cell proliferation and oncogenesis is believed to stem from its ability to 
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target and repress the tumor suppressor genes, p16INK4A and p14ARF which reside in the 
CDKN2A locus (cyclin-dependent kinase inhibitor 2A) (Agherbi et al., 2009; Bracken et al., 
2007; Kotake et al., 2007).  During cellular senescence, EZH2 levels are downregulated 
which coincides with decreases in H3K27 tri-methylation and the activation of the tumor 
suppressor genes.  These observations highlight the importance of proper regulation of EZH2 
levels and functions in the cell. 
Post-translational modification is one mechanism by which protein function can be 
regulated.  Protein phosphorylation is a well-characterized modification that has been 
identified in numerous proteins particularly those involved in cell signaling pathways.  
Regulatory functions of phosphorylation include, but are not limited to, modulation of 
enzyme activity, mediation of protein-protein interaction, and contribution to protein stability 
or instability.  Several chromatin-modifying enzymes were reported to be regulated by 
phosphorylation.  The best example involves phosphorylation of histone deacetylases 
(HDACs) which regulates their distribution between the nucleus and cytoplasm (Grozinger 
and Schreiber, 2000; McKinsey et al., 2000a; McKinsey et al., 2000b; Parra et al., 2005; 
Vega et al., 2004; Zhang et al., 2002; Zhang et al., 2001).   
At the commencement of the work described in this chapter, one study reported that 
EZH2 can be phosphorylated at serine 21 by the kinase Akt which inhibits its enzymatic 
function (Cha et al., 2005).  This observation was especially interesting as it illustrates how 
environmental cues can induce epigenetic changes needed to alter gene expression by 
entwining epigenetic and cell signaling pathways.  Therefore, I set out to identify novel sites 
of EZH2 phosphorylation for three reasons: (1) EZH2 is a large protein (mouse EZH2 is 746 
amino acids in length) and contains many serine, threonine, and tyrosine residues that can 
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potentially be phosphorylated, (2) regulation of EZH2 function is important as illustrated by 
its overexpression in human cancers and its involvement in repressing tumor suppressor 
genes, and (3) EZH2 is essential for normal early embryonic development, a process which 
involves the activation of signaling pathways that drive a cell to a specific lineage.  In this 
chapter, I confirm and extend the findings of Cha et al. and demonstrate that mouse EZH2 is 
a phospho-protein that contains other phosphorylation sites in addition to serine 21.  
Moreover, I identify a region of EZH2 that is threonine phosphorylated and provide evidence 
that the HMT activity of PRC2 can be regulated by phosphorylation.   
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RESULTS 
 
Serine 21 is not a major EZH2 phosphorylation site 
EZH2 has previously been reported to be a phosphoprotein (Cha et al., 2005).  To 
confirm this finding, HEK293T cells exogenously expressing Flag-tagged wildtype EZH2 
were metabolically labeled with [γ-32P]ATP.  Following Flag immunoprecipitation, bound 
proteins were treated with or without protein phosphatase 1 (PP1) or λ protein phosphatase 
(λ-PPase).  The resulting autoradiogram confirms that EZH2 is indeed phosphorylated and 
treatment with either PP1 or λ-PPase diminishes the signal (Figure 3.1A, lanes 2-4).  Western 
blot analysis using Flag antibodies verifies that Flag-tagged EZH2 is present at relatively 
similar amounts in all three lanes. 
Given that EZH2 can be phosphorylated at serine 21 by the kinase Akt (Cha et al., 
2005), I was interested in determining whether serine 21 is the major site of EZH2 
phosphorylation.  Alternatively, it was possible (and highly likely) that other phosphorylation 
sites existed given the number of serines, threonines, and tyrosines present within the protein.  
To address this question, a parallel metabolic labeling experiment was performed using 
HEK293T cells exogenously expressing Flag-tagged EZH2 where serine 21 was mutated to 
an alanine (S21A).  This experiment indicated that the S21A mutant was also 
phosphorylated, roughly to the same degree as wildtype EZH2 (Figure 3.1A, lanes 5-7).  
Hence, these observations not only confirm the finding that EZH2 is a phospho-protein but 
also demonstrate that EZH2 contains other phosphorylation sites, in addition to serine 21, 
which I set out to explore. 
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Phosphorylation of PRC2 inhibits HMT activity  
Protein phosphorylation can have profound functional consequences including effects 
on enzymatic activity, protein-protein interactions, cellular localization, and protein stability.  
Serine 21 phosphorylation inhibits the enzymatic activity of EZH2 as mutation of serine 21 
to alanine resulted in a 3-fold increase in HMT activity (Cha et al., 2005).  In addition, when 
Akt is inhibited, global levels of H3K27 tri-methylation increase (Cha et al., 2005).  
However, Ru Cao reconstituted the PRC2 complex with wildtype and S21A EZH2 and found 
that both forms exhibited similar levels of HMT activity (data not shown).  Furthermore, I 
examined H3K27me3 levels by western blot when HeLa cells were treated with or without 
the PI3K-Akt kinase inhibitor, LY294002, and saw no changes in H3K27me3 levels (data 
not shown).  These reason for these discrepancies are unclear at the moment. 
Nevertheless, given that other phosphorylation sites exist within EZH2 coupled with 
the observation that other components of the PRC2 complex are phosphorylated (data not 
shown), I investigated the possibility that phosphorylation of PRC2 can affect its HMT 
activity.  To address this question, HEK293T cells were transfected with 4 components of the 
PRC2 complex: EZH2, SUZ12, and EED that comprise the core complex, as well as AEBP 
(adipocyte enhancer binding protein) which stimulates the enzymatic activity of the core 
complex.  The complex was immunoprecipitated using Flag antibodies and treated with or 
without PP1.  A fraction of bound proteins were analyzed by western blot (Figure 3.1B) 
while the remaining proteins were subjected to an in vitro HMT assay using PRC2 complex 
reconstituted from Sf9 cells as a positive control.  The autoradiogram indicates that when the 
immunoprecipitated complex is treated with PP1, an increase in methylated histones is 
observed (Figure 3.1C).  This indicates that phosphorylation of PRC2 inhibits its HMT 
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activity which is consistent with the findings of Cha et al.  Thus, it appears that 
phosphorylation of PRC2 can have a profound consequence on its enzymatic function. 
 
EZH2 is threonine phosphorylated which is regulated by PP1/PP2A 
Given that the data above demonstrates the existence of other EZH2 phosphorylation 
sites in addition to serine 21, I set out to identify and characterize novel phosphorylation sites 
of EZH2.  To narrow down which amino acids of EZH2 are phosphorylated, I took 
advantage of antibodies recognizing phospho-serine, phospho-threonine, and phospho-
tyrosine.  HEK293T cells were transfected with Flag-tagged EZH2 which was subject to 
immunoprecipitation.  Bound proteins were treated with or without λ-PPase which is capable 
of removing the phospho-group from all three residues.  Western blot analysis using the 
residue-specific phospho-antibodies revealed that EZH2 is threonine phosphorylated which 
diminishes upon treatment with λ-PPase (Figure 3.2A).  Although a band was detected in the 
phospho-serine western blot, this band does not diminish upon λ-PPase treatment suggesting 
that these bands are likely the result of overexposure.  However, it remains possible that 
EZH2 can be serine- or tyrosine-phosphorylated as detection of these modifications depends 
on both the quality of the antibody as well as the abundance of the modification. 
Protein phosphorylation is regulated by the competing actions of kinases and 
phosphatases.  The human genome encodes for over 500 kinases (Manning et al., 2002) that 
exhibit a range of specificity and targets.  In contrast, protein phosphatases are easily grouped 
by the types of residues which they remove phosphate groups from.  Serine/threonine 
phosphatases which are classified into 6 families (PP1-PP6) possess a catalytic subunit to 
execute dephosphorylation and a regulatory subunit which confers substrate specificity.  
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Given that earlier experiments demonstrated that PP1 can dephosphoryate EZH2 in vitro 
(Figure 3.1A), I examined the effect of a PP1 inhibitor, okadaic acid on EZH2 threonine 
phosphorylation in cells.  HEK293T cells exogenously expressing Flag-tagged EZH2 were 
treated with okadaic acid for various times.  Threonine phosphorylated EZH2 was detected 
by Flag immunoprecipitation followed by western blot analysis.  Results shown in Figure 
3.2B demonstrate that threonine phosphorylated EZH2 increases upon treatment with 
okadaic acid.  Although this supports the notion that PP1 can utilize EZH2 as a substrate, it 
should be noted that okadaic acid also inhibits PP2A.  Therefore, further work involving the 
use of other phosphatase inhibitors is required to determine the contributions of PP1, PP2A, 
and possibly other phosphatases to EZH2 dephosphorylation.   
 
Majority of threonine phosphorylation of EZH2 occurs in the region aa351-593  
 To identify which threonines of EZH2 are phosphorylated, I utilized a mapping 
strategy employing deletion mutants to determine which region of EZH2 can be threonine 
phosphorylated (Figure 3.3A).  Deletion 1 and 2 were constructed and tested first in order to 
narrow down which region to focus on.  Results shown in Figure 3.3B demonstrate that 
similar to wildtype, deletion 1 is threonine phosphorylated whereas deletion 2 is not.  This 
suggests that threonine phosphorylation occurs at the C-terminal half of EZH2.  To further 
narrow down the region, two additional deletion mutants were constructed (Figure 3.3A).  
Deletion 3, but not deletion 4, was threonine phosphorylated (Figure 3.3C).  Furthermore, 
when cells were treated with okadaic acid, an enrichment of threonine phosphorylation was 
observed in deletion 1 and 3 indicating that these phosphorylation site(s) can be regulated by 
PP1 and/or PP2A (Figure 3.3C). 
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 Results from the deletion mutant mapping experiments indicated that threonine 
phosphorylation site(s) reside in the region encompassing amino acid residues 351-593 of 
EZH2.  Within this region are thirteen threonine residues, twelve of which were singly 
mutated to alanines by site-directed mutagenesis of deletion 3.  (Note: The remaining site, 
T487 is discussed in Chapter 4).  Single point mutants of deletion 3 were tested for threonine 
phosphorylation as shown in Figure 3.3D.  Interestingly, mutation of several sites had a 
profound effect on total threonine phosphorylation.  Theronines residing within the N-
terminal end of the fragment (T367, T369, T378, T386, and T388) appear to be major sites of 
phosphorylation as mutation of these residues dramatically reduced detection of the 
phosphorylated species. 
 In particular, mutation of T378 within deletion 3 caused the most obvious decrease in 
threonine phosphorylation.  Therefore, this residue was mutated to alanine by site directed 
mutagenesis of full length EZH2.  Although EZH2 T378A exhibits diminished threonine 
phosphorylation, the effect was quite modest (Figure 3.3E compare lane 3 to 5).  One 
possible explanation for this observation is that when T378 is mutated, the responsible kinase 
is less discriminatory and phosphorylates nearby sites.  Figure 3.3D supports this notion as 
threonines residing within 10 amino acids of T378 appear to be phosphorylated to some 
extent.  Therefore, these threonines were mutated in conjunction with T378 in two different 
combinations, T367A/T369A/T378A (labeled as “1/2/3”) and T378A/T386A/T388 (labeled 
as “3/4/5”) as shown in Figure 3.3E (lane 7 and 9).  Both combinatorial mutants are 
dramatically less phosphorylated when compared to wildtype EZH2 and demonstrate that 
these 5 threonines can be modified by phosphorylation. 
 88 
 The effect of inhibiting PP1/PP2A by okadaic acid was also tested.  While T378A 
and T378A/T386A/T388 (labeled as “3/4/5”) still exhibited enrichment of threonine 
phosphorylation upon treatment, there was no effect when cells expressing 
T367A/T369A/T378A (labeled as “1/2/3”) were treated with okadaic acid (Figure 3.3E 
compare lanes 3 and 4, 5 and 6, 9 and 10 to lanes 7 and 8).  This observation suggests that 
T367, T369, and T378 are residues that are significantly regulated by PP1/PP2A.  Although 
additional work is required to discern the contribution of PP1 and PP2A to 
dephosphorylation of T367, T369, and T378, it is evident that these residues in addition to 
T386 and T388 are major sites of threonine phosphorylation.   
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DISCUSSION 
 
 In summary, the data presented in this chapter demonstrates that EZH2 is threonine 
phosphorylated.  By deletion mutant mapping analysis, I found that the vast majority of this 
phosphorylation occurs in the region aa351-593 with T367, T369, T378, T386, and T388 
contributing the most.  Furthermore, threonine phosphorylation is enriched when cells are 
treated with okadaic acid which suggests that phosphatases PP1 and/or PP2A contribute to 
the regulation of this modification.  Importantly, phosphorylation of PRC2 inhibits its HMT 
activity although the contribution of the aforementioned sites remains to be determined.  This 
observation is consistent with the previous study regarding Akt-mediated EZH2 
phosphorylation (Cha et al., 2005). 
 This study highlights the difficulty of identifying novel phosphorylation sites.  In 
general, two approaches are commonly used:  deletion mutant mapping and mass 
spectrometry.  Although tedious, deletion mutant mapping followed by mutational analysis 
can provide insight into the regions where the phosphorylation site(s) exist.  However, 
interpretation of these experiments can be problematic particularly if various phosphorylation 
sites reside in different regions of the protein.  One must also consider implications on the 
overall structure when portions of the protein are deleted since mutants may not mimic the 
structure of the native protein.  Furthermore, kinases can be indiscriminant when presented 
with a point mutant and phosphorylate nearby residues making interpretation of data even 
more difficult.  More importantly, this approach requires that the site be abundantly 
phosphorylated to facilitate detection by western blot using amino acid-specific phospho-
antibodies.  Residues that contribute to a minority of all phosphorylation events within the 
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protein may have a profound impact on protein function, but they are very difficult to 
identify by this method.  On the other hand, these issues are circumvented when mass 
spectrometry is used to identify novel phosphorylation sites.  Here, the phospho-protein is 
subjected to tryptic digest which cleaves the protein at defined sites generating peptides 
whose masses can be measured and identified by comparison to the predicted mass.  Mass 
spectrometry is quite sensitive and can be quantitative in some cases.  However, not all 
peptides are detected by mass spectrometry and thus an important phosphorylation site may 
be missed simply because of insufficient coverage of the protein.  It should be noted that 
attempts to identify novel EZH2 phosphorylation sites by mass spectrometry were 
unsuccessful due to this issue of insufficient coverage.  
 Nevertheless, through deletion mutant mapping, I identified T367, T369, T378, T386, 
and T388 as putative EZH2 phosphorylation sites.  Although these residues are conserved in 
humans and mice, they are not conserved in flies while T386 and T388 are also not 
conserved in zebrafish.  This observation does not preclude the possibility of a functional 
consequence, but it certainly makes the decision to characterize these phosphorylation sites 
less attractive.  However, since the completion of this work, several high throughput 
phosphoproteomic studies utilizing mass spectrometry have confirmed that T367 is 
phosphorylated (Brill et al., 2009; Chen et al., 2009; Huttlin et al., 2010; Malik et al., 2009).  
Interestingly, a conserved proline residue immediately follows T367.  This type of 
phosphorylation is called proline-directed phosphorylation and is known to be deregulated in 
neurodegenerative diseases such as Alzheimer’s disease and cancer (Lu, 2004; Lu et al., 
2002).  In relation to the adjacent phosphorylated residue, this proline can exist in cis or in 
trans conformations.  Conversion between these two forms can occur spontaneously (albeit 
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at a very slow rate) but efficient isomerization is generally catalyzed by a specific subgroup 
of peptidyl-prolyl isomerases from the Pin-1 family.  The conformation of the proline residue 
can alter the local or global structure of the protein and thus, has the potential to regulate 
protein function in biological proceses.  Proline-directed kinases include the cyclin dependent 
kinases (CDKs), mitogen activated kinases (MAPKs), Jun N-terminal kinase (JNK), and 
glycogen synthase kinase (GSK).  These kinases are attractive candidates for the 
phosphorylation of EZH2 at T367 and can be easily be tested through in vitro and in vivo 
experiments.   
Additional work is required to determine the functional consequences of these novel 
phosphorylation sites.  Although all five putative phosphorylation sites do not reside in a 
functional domain, they are located in between two SANT domains (named after the proteins 
initially discovered to contain this conserved domain: switching-defective protein 3 (Swi3), 
adaptor 2 (ada2), nuclear receptor co-repressor (N-CoR), transcription factor IIIB’ 
(TFIIIB’)).  The sequence of this domain exhibits strong similarity to the DNA-binding 
domain of Myb-related proteins (Aasland et al., 1996) but it appears to be functional distinct 
from Myb and its related proteins.  Emerging evidence has indicated that the SANT domain 
plays a central role in chromatin remodeling through its ability to bind to histone tails (Boyer 
et al., 2004).  Thus, the novel phosphorylation sites identified in this chapter may contribute 
to the binding of EZH2 to either histones or DNA itself.  Gel shift assays utilizing 
chromatinized DNA and the PRC2 complex reconstituted with wildtype or mutant EZH2 will 
undoubtedly address this possibility. 
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EXPERIMENTAL PROCEDURES 
 
Cell culture, transfections, and okadaic acid treatment.  HEK293T cells were cultured in 
Dulbecco’s modified eagle medium (DMEM) supplemented with 10% fetal bovine serum 
and penicillin/streptomycin.  Transfections were performed using Lipofectamine 2000 
(Invitrogen cat# 11668-019).  Okadaic acid was purchased from Sigma (cat# O7885) and 
used at a final concentration of 100 nM. 
 
Expression plasmids.  cDNA for mouse EZH2, human SUZ12, human EED, and human 
AEBP2 were subcloned into the mammalian expression vector, pcDNA3-Flag.  The 
restriction sites used were 5’ and 3’ BamHI for EZH2 and 5’EcoRI and 3’XhoI for Suz12, 
EED, and AEBP2.  Deletion mutants were subcloned using the primers listed in Table 3.1.  
Site-directed mutagenesis was performed using the Stratagene QuikChange II XL kit 
(Agilent cat# 200521) and mutagenesis primers listed in Table 3.2.  All constructs were 
verified by sequencing using the primers listed in Table 3.3. 
 
Antibodies.  The following antibodies were used in this chapter: Flag M2 mouse monoclonal 
(Sigma cat# F3165), mouse phospho-serine (Chemicon cat# AB1603), mouse phospho-
threonine (Cell Signaling cat# 9386), and mouse phospho-tyrosine 4G10 (gift from Weiguo 
Zhang, Duke). 
 
Cell extract preparation and immunoprecipitation.  Cell pellets were resuspended with 
RIPA lysis buffer consisting of 50 mM Tris (pH 7.4), 1% NP-40, and 150 mM NaCl 
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supplemented with protease and phosphatase inhibitors (Roche Complete Protease Inhibitors 
cat# 11697498001 and Roche PhosSTOP cat# 04906837001).  Lysates were incubated on ice 
for 45 minutes and subjected to centrifugation at 17000 x g for 15 minutes at 4°C.  The 
resulting supernatant was transferred to a new tube and protein concentration of the lysate 
was determined by Bradford assay (BioRad Protein Assay cat# 500-0006).  For Flag 
immunoprecipitations, 30 µL of α-Flag M2 affinity gel (Sigma cat# A2220) was added to the 
lysates and rotated at 4°C overnight.  Bound proteins were washed 3 times with RIPA lysis 
buffer prior to the addition of 2X SDS loading buffer.  Bound proteins were then subjected to 
SDS-PAGE and western blot analysis. 
 
Western blot analysis.  Proteins resolved by SDS-PAGE were transferred onto 
nitrocellulose membranes (BioRad cat# 162-0112).  Blots were blocked with 5% nonfat milk 
in TBST (50mM Tris, pH 7.4, 150 mM NaCl, 0.05% Tween) for 1 hour at room temperature 
followed by a quick rinse with TBST.  Primary antibodies were diluted in TBST and added 
to the blots for overnight incubation at 4°C.  Following a quick TBST rinse, secondary 
antibodies diluted in TBST were added.  Blots were washed 3 times with TBST prior to 
chemiluminescence detection (ECL Western blotting susbtrate, Pierce cat# 32106).  When 
applicable, blots were stripped using RestoreTM Plus Western Blot Stripping Buffer (Pierce 
cat# 46428). 
 
Metabolic labeling.  Phosphate-free media was prepared using DMEM without sodium 
phosphate (Gibco cat# 11971) supplemented with 10% FBS which was dialyzed overnight 
against Tris-buffered saline (50mM Tris, pH 7.4, 150 mM NaCl) using 3500 MWCO dialysis 
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tubing.  Transfected HEK293T cells were first washed once with phosphate-free media then 
labeled with phosphate-free media containing 1mCi [γ-32P]ATP (Perkin Elmer cat# 
NET155001MC) for 3.5 hours at 37°C.  Cells were harvested and subjected to RIPA lysis 
and Flag immunopreciptation as described above.   
 
Phosphatase reaction.  Phosphatase treatment using PP1 (New England Biolabs cat# P0754) 
and λ-PPase (New England Biolabs cat# P0753) was performed as outlined by the 
manufacturers’ protocols.  Briefly, immunoprecipitated proteins were incubated with 1 µL of 
phosphatase in the supplied reaction buffer for 1 hour at 30°C.   
 
Histone methyltransferase (HMT) assay.  To assess HMT activity, immunoprecipitated 
PRC2 complex was first washed with BC50 (40 mM Hepes, pH 7.9, 0.2 mM EDTA, 50 mM 
KCl, 10% glycerol, 1mM DTT, 0.2 mM PMSF) three times.  Bound proteins were subjected 
to an HMT reaction consisting of 4 µg of chicken oligonucleosomes, 1 µCi of [H3]-S-
adenosyl-methionine, and HMT buffer (20 mM Tris, pH 8.0, 4 mM EDTA, 0.5 mM DTT) in 
a total volume of 50 µL.  Reactions were incubated at 30°C for 1 hour and terminated by the 
addition of SDS loading buffer followed by boiling at 95°C for 10 minutes.  10% of the 
reaction was used for western blot analysis.  The remaining reaction was resolved by 18% 
SDS-PAGE which was then incubated with En3Hance (Perkin Elmer cat# 6NE9701) for 40 
minutes at room temperature followed by a 10 minute wash with dH2O.   The gel was then 
dried on filter paper and exposed to film for 24 hours.  The reconstituted PRC2 complex used 
as a positive control was purified from Sf9 insect cells and was described previously (Cao 
and Zhang, 2004). 
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Figure 3.1 Phosphorylation of PRC2 inhibits HMT activity.   
(A) EZH2 is a phosphoprotein.  HEK293T cells exogenously expressing Flag-tagged EZH2 
or S21A were radiolabeled with [γ-32P]ATP.  Following immunoprecipitation using Flag 
antibodies, bound proteins were treated with no phosphatase, with PP1, or λ-PPase.  
Autoradiography confirms that EZH2 is phosphorylated and that the signal diminishes upon 
phosphatase treatment.  Western blot analysis using Flag antibodies verifies equal amounts of 
protein.   
 
(B) Flag western blot of exogenous PRC2 complex that was immunoprecipitated from 
HEK293T cells and treated with or without PP1.   
 
(C) Phosphatase treatment of the PRC2 complex enhances HMT activity.  
Immunoprecipitated PRC2 complex from (B) was subjected to a HMT assay using [3H]-S-
adenosyl-methionine as the methyl donor.   
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Figure 3.1 (continued) 
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Figure 3.2 Threonine phosphorylation of EZH2 is regulated by PP1/PP2A. 
(A) EZH2 is threonine phosphorylated.  Flag-EZH2 was transfected into HEK293T cells and 
immunoprecipitated using Flag antibodies.  Bound proteins were treated with or without λ-
PPase and subjected to western blot analysis using antibodies specific for phospho-serine, 
phospho-threonine, and phospho-tyrosine.   
 
(B) Okadaic acid treatment enriches levels of EZH2 threonine phosphorylation.  HEK293T 
cells were transfected with Flag-tagged EZH2 and treated with 100 nM okadaic acid for the 
times indicated.  EZH2 was immunoprecipitated using Flag antibodies and western blot 
analysis was performed using phospho-threonine and Flag antibodies.   
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Figure 3.3 Majority of threonine phosphorylation occurs in region aa351-593. 
(A) Schematic diagram of the deletion mutants constructed.   
 
(B) Deletion 1 is threonine phosphorylated.  Wildtype EZH2, deletion 1, and deletion 2 were 
transfected into HEK293T cells and immunoprecipitated using Flag antibodies.  Western blot 
analysis using phospho-serine, phospho-threonine, and phospho-tyrosine reaveals that 
deletion 1, but not deletion 2, is threonine phosphorylated.   
 
(C) Deletion 3 is threonine phosphorylated which can be enriched after okadaic acid 
treatment.  Wildtype EZH2, deletion 1, deletion 3, and deletion 4 were transfected into 
HEK293T cells.  24 hours post-transfection, cells were treated with 100 nM okadaic acid for 
4 hours and then harvested.  Flag immunoprecipitation followed by western blot analysis 
using the antibodies indicated demonstrates that deletion 3 is also threonine phosphorylated 
which can be enriched upon okadaic acid treatment.   
 
(D) Single point mutants corresponding to each threonine were introduced into deletion 3 and 
tested for threonine phosphorylation.  Constructs were transfected into HEK293T cells.  
Flag-tagged mutants were immunoprecipitated and subjected to western blot analysis using 
phospho-threonine and Flag antibodies.  For reference purposes, each mutant is numbered 1 
through 12 as indicated. 
 
(E) Combinatorial point mutants were constructed in the context of full length EZH2.  Cells 
expressing these mutants were treated with or without okadaic acid and tested for threonine 
phosphorylation as described in (C).  The residues that are mutated correspond to the 
numbering system in (D) where “3” represents T378A, “1/2/3” represents 
T367A/T369A/T378A, and “3/4/5” represents T378A/T386A/T388A. 
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Figure 3.3 (continued) 
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Table 3.1   Primers used for PCR-cloning of EZH2 deletion mutants. 
 
Mutant Forward Primer Reverse Primer 
Deletion 1 GGCCCCTCTGCTAACCATG CTTTTAGCGGCCGCTCAGTCAGGGTCACACTCTCGGA 
Deletion 2 GGCCCCTCTGCTAACCATG CTTTTAGCGGCCGCTCATGGGCGTTTAGGTGGTGT 
Deletion 3 GTTAGGATCCGCTGAGCGTATAAAGACACCAC 
GATTGCGGCCGCTTAATGGTCAGCAG
CTCCACAC 
Deletion 4 GTTAGGATCCTGCTACCTGGCTGTCCGA GATTGCGGCCGCTTATCAAGGGATTTCCATTTCTCG 
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Table 3.2   Mutagenesis primers used in Chapter 3. 
 
Primer Forward Primer Reverse Primer 
T367A TAGCAGACCCAGCGCCCCCACCATCAG CTGATGGTGGGGGCGCTGGGTCTGCTA 
T369A CCCAGCACCCCCGCCATCAGTGTGC GCACACTGATGGCGGGGGTGCTGGG 
T378A TGCTGGAGTCAAAGGATGCAGACAGTGACAGAGA 
TCTCTGTCACTGTCTGCATCCTTTGACTCC
AGCA 
T386A GACAGAGAAGCAGGGGCTGAAACTGGGGGAG 
CTCCCCCAGTTTCAGCCCCTGCTTCTCTGT
C 
T388A ACAGAGAAGCAGGGACTGAAGCTGGGGGAGAG 
CTCTCCCCCAGCTTCAGTCCCTGCTTCTCT
GT 
T404A GAAGAGAAAAAAGATGAGGCGTCCAGCTCCTCTGAA 
TTCAGAGGAGCTGGACGCCTCATCTTTTTT
CTCTTC 
T416A CCTCTGAAGCAAATTCTCGGTGTCAAGCACCAATAAAGATG 
CATCTTTATTGGTGCTTGACACCGAGAATT
TGCTTCAGAGG 
T446A CATGTTTAGAGTCCTCATTGGTGCTTACTACGATAACTTTTGTGC 
GCACAAAAGTTATCGTAGTAAGCACCAAT
GAGGACTCTAAACATG 
T460A ATTGCTAGGCTAATTGGGGCCAAAACATGTAGACAGG 
CCTGTCTACATGTTTTGGCCCCAATTAGCC
TAGCAAT 
T462A TAGGCTAATTGGGACCAAAGCATGTAGACAGGTGTATG 
CATACACCTGTCTACATGCTTTGGTCCCAA
TTAGCCTA 
T482A CATAGCACCTGTTCCCGCTGAGGATGTAGACAC 
GTGTCTACATCCTCAGCGGGAACAGGTGC
TATG 
T568A AAAGCACAATGCAACGCCAAACAGTGTCCATGC 
GCATGGACACTGTTTGGCGTTGCATTGTG
CTTT 
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Table 3.3   EZH2 sequencing primers. 
 
Primer Type Sequence 
Flag forward   GGCCCCTCTGCTAACCATG 
EZH2 INT1 forward   GACAGAGAATGTGGATTTAT 
EZH2 INT2 forward   TGGAGTGGTGCTGAAGCCTC 
EZH2 INT3 forward   TGCAACACCCAACACATATAAGA 
EZH2 INT4 forward   GTAGCATTCAGCGGGGCT 
EZH2 INT5 reverse   TTCCGAGGTGGGCAAGTT 
EZH2 INT6 reverse   GGCTGTATCCTCCGCTGC 
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CHAPTER 4 
 
CDK1-MEDIATED PHOSPHORYLATION OF EZH2 REGULATES ITS STABILITY 
 109 
ABSTRACT 
 
 The H3K27 histone methyltransferase, EZH2 (enhancer of zeste 2) is a Polycomb 
protein that plays an important role in the numerous biological processes including multi-
cellular development, stem cell biology, and cancer development.  Upregulation of EZH2 is 
often observed in human cancers including prostate cancer where high levels of EZH2 is 
associated with the worst prognosis for the patient.  The role of EZH2 in cancer development 
is believed to stem from its ability to repress the tumor suppressor locus, CDKN2A which 
highlights the importance of regulating EZH2 function.  In this chapter, I demonstrate that 
EZH2 can be regulated by the cyclin dependent kinase, CDK1 which phosphorylates EZH2 
at T345 and T487.  Consistent with the cell cycle phase in which CDK1 activity is the 
highest, EZH2 phosphorylation is enriched in cells arrested at mitosis compared to S phase.  
Phosphorylation of T345 and T487 causes EZH2 to be ubiquitinated and degraded by the 
proteasome.  Furthermore, mutation of these residues confers a proliferative disadvantage 
compared to cells expressing wildtype EZH2 suggesting that phosphorylatin of EZH2 is 
important for cell proliferation.  Collectively, these results establish a novel role for CDK-
mediated EZH2 phosphorylation whereby protein stability is regulated. 
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INTRODUCTION 
 
 The Polycomb group protein, EZH2 (enhancer of zeste 2) is an important epigenetic 
regulator that mediates transcriptional repression through its histone methyltransferase 
(HMT) activity.  It is the catalytic subunit of Polycomb Repressive Complex 2 (PRC2) and 
requires PRC2 core components SUZ12 (Suppressor of zeste) and EED (Embryonic 
ectoderm development) to carry out tri-methylation of lysine 27 of histone H3 (Cao et al., 
2002; Cao and Zhang, 2004a; Czermin et al., 2002; Kuzmichev et al., 2002; Muller et al., 
2002).  EZH2 plays a significant role in epigenetic gene silencing and has been linked to 
diverse biological processes including developmental patterning, X-inactivation, and stem 
cell pluripotency (Cao and Zhang, 2004b; Lee et al., 2006; Plath et al., 2003).   
 In addition, a number of studies have described a role for EZH2 in cell proliferation 
and oncogenesis.  Ectopic expression of EZH2 confers a proliferative advantage in primary 
cells (Bracken et al., 2003).  Compared to normal tissues, EZH2 is often aberrantly 
overexpressed in a variety of human cancers including prostate cancer (Simon and Lange, 
2008; Varambally et al., 2002).  In fact, higher expression of EZH2 in the prostate correlates 
with the worst prognosis for the patient (Varambally et al., 2002).  On the other hand, cell 
proliferation and migration can be mitigated by RNA interference of EZH2 (Bracken et al., 
2003; Varambally et al., 2008; Varambally et al., 2002). 
Although Polycomb proteins are best known for maintaining the repression of HOX 
genes during development, they have also been implicated in silencing the CDKN2A (cyclin 
dependent kinase inhibitor 2A) locus that encodes for the tumor suppressor gene p16INK4A.  
In young proliferating cells, evasion of senescence requires repression of this locus mediated 
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by EZH2 and H3K27 tri-methylation (Agherbi et al., 2009; Bracken et al., 2007; Kotake et 
al., 2007).  Consistent with this, EZH2 expression is high in proliferating cells but is 
downregulated in stressed and senescing cells.  Hence, it believed that overexpression of 
EZH2 contributes to oncogenesis by inappropriately silencing tumor suppressor genes.   
These observations illustrate the importance of proper regulation of EZH2 function in 
the cell.  However, only a few studies have investigated how the function of EZH2 is 
controlled.  Transcription of the EZH2 gene is regulated by the pRB-E2F pathway and peaks 
during the G1 to S phase transition (Bracken et al., 2003).  Degradation of EZH2 mRNA can 
be targeted by miR-101 whose expression decreases during cancer progression (Varambally 
et al., 2008) which provides one explanation as to how EZH2 levels are deregulated in 
cancer.  One study also reported that Akt phosphorylates EZH2 at serine 21 and inhibits its 
HMT activity (Cha et al., 2005).  Thus, it appears that EZH2 is regulated at the 
transcriptional, post-transcriptional, and post-translational level.   
As discussed in the introduction of Chapter 3, regulation of protein function can be 
mediated by post-translational modifications including phosphorylation.  The consequences 
of phosphorylation include effects on enzymatic activity, protein-protein interactions, 
subcellular localization and protein stability.  Given that phosphorylation has been reported 
to regulate EZH2 (Cha et al., 2005) as well as other chromatin-associated proteins including 
histone deacetylaces (Grozinger and Schreiber, 2000; McKinsey et al., 2000a; McKinsey et 
al., 2000b; Parra et al., 2005; Vega et al., 2004; Zhang et al., 2002; Zhang et al., 2001) and 
the Polycomb protein, BMI1 (Voncken et al., 2005; Voncken et al., 1999), I set out to further 
investigate mechanisms of EZH2 regulation involving phosphorylation. 
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In the previous chapter, I presented evidence demonstrating that EZH2 is a phospho-
protein and that phosphorylation sites in addition to serine 21 exist.  My data also established 
that threonine phosphorylation was abundant in EZH2.  Although deletion mutant mapping 
of EZH2 indicated the presence of threonine phosphorylation in the region aa351-593, 
further work revealed the absence of a single residue that contributed to the majority of 
threonine phosphorylation in EZH2.  Furthermore, while these threonines are conserved in 
humans and mice, they are not conserved in flies and in some cases zebrafish.  Although this 
does not preclude the possibility of a functional consequence, these observations were 
sufficient to dissuade me from further characterizing these putative phosphorylation sites.    
Using an alternative approach described below, this chapter discusses the 
identification and characterization of two novel EZH2 phosphorylation sites, T345 and T487.  
These highly conserved residues are phosphorylated by the cyclin dependent kinase, CDK1.  
Consistent with the cell cycle stage in which CDK1 exhibits peak kinase activity, phospho-
EZH2 enrichment is observed during mitosis.  Interestingly, phospho-EZH2 possesses a 
shorter half life compared to total Ezh and is degraded by the ubiquitin pathway.  Thus, these 
studies provide the first demonstration of cell cycle regulation of EZH2 protein levels by 
phosphorylation. 
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RESULTS 
 
EZH2 is phosphorylated at T345 and T487 
To determine which putative EZH2 phosphorylation sites to further characterize, I 
utilized a combination of phosphorylation site prediction programs including MotifScan and 
NetPhos coupled with previously published phosphoproteomic data.  With this approach, two 
putative phosphorylation sites were of great interest, threonines 345 and 487.  Under the 
highest stringency, both programs returned these two sites and in the case of MotifScan, they 
were the only two sites that were scored within the top 1%.  Previous phosphoproteomic 
studies involving mass spectrometry also identified T345 and T487 of EZH2 to be 
phosphorylated (Beausoleil et al., 2004; Choudhary et al., 2009).  These residues are highly 
conserved in humans, mice, and zebrafish while T487 is also conserved in flies (Figure 
4.1A).   
However, the most convincing observation that persuaded me to characterize these 
sites was the presence of a CDK1-substrate consensus motif (S/T-P-X-R/K).  CDK1 is a 
cyclin dependent kinase that is active during mitosis and is required for the progression of 
this stage of the cell cycle.  Given that previous reports demonstrated the importance of 
EZH2 cell proliferation (Bracken et al., 2003) coupled with the observation that knockdown 
of EZH2 in prostate cells resulted in an accumulation of cells in G2/M (Varambally et al., 
2002), these two putative phosphorylation sites were of great interest.   Thus, I set out to 
confirm that T345 and T487 are indeed residues of EZH2 that can be phosphorylated by 
CDK1 and determine the functional consequence(s) of their phosphorylation. 
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I began this work by generating antibodies that specifically recognize these 
phosphorylation sites.  After injecting rabbits with phosphorylated peptides encompassing 
these residues, I performed a two-step affinity purification of the antibody by first removing 
antibodies recognizing the unphosphorylated and pan peptides followed by purification of 
antibodies recognizing the phosphorylated peptide.  Dot blot analysis confirms that the 
affinity-purified antibodies recognize the phosphorylated peptides with specificity of over 
64-fold compared to the unphosphorylated peptide (Figure 4.1B).  Furthermore, both 
phospho-specific antibodies recognize exogenously expressed wildtype EZH2 that was 
immunoprecipitated, but not when the site of phosphorylation was mutated to an alanine 
(Figure 4.1C). 
After demonstrating the specificity of both phospho-EZH2 antibodies, it was 
imperative to determine whether endogenous pT345 and pT487 was present in cells.  To 
address this question, western blot analysis of HeLa and NIH3T3 subcellular extracts was 
performed using the phospho-specific antibodies.  Additionally, recombinant PRC2 complex 
purified from Sf9 cells was also tested.  Probing the blot with the pT345 antibody resulted in 
detection of a band corresponding to the size of recombinant EZH2 as well as a slower 
migrating band in both the HeLa nuclear extract and nuclear pellet (Figure 4.1D, top panel).  
On the other hand, western blot analysis with the pT487 antibody clearly detected one band 
corresponding to the size of EZH2 in the NIH3T3 nuclear extract and the HeLa nuclear pellet 
(Figure 4.1E, bottom panel).  When more protein was loaded, I was also able to detect pT487 
in HeLa nuclear extracts (data not shown).  It should be noted that the pT487 antibody was 
raised against the mouse sequence which contains one unconserved amino acid compared to 
the human sequence which might account, in part, for the decreased sensitivity towards 
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pT487 in HeLa nuclear extracts compared to NIH3T3 nuclear extracts.  Nevertheless, using 
these phospho-EZH2 antibodies, I was able to detect bands corresponding to the size of 
recombinant EZH2.   
To further confirm that the detected bands are indeed phosphorylated EZH2, HeLa 
cells stably expressing shRNAs targeting EZH2 were generated by lentiviral infection.  
Following puromycin selection, RNA was extracted and RT-qPCR was performed to 
determine the relative expression of EZH2.  As shown in Figure 4.1E (top panel), EZH2 
knockdown was achieved with an efficiency of roughly 80%.  Consistent with this 
observation, a dramatic decrease in EZH2 protein levels was also detected (Figure 4.1E, 
bottom panel).  Furthermore, western blot analysis using both phospho-EZH2 antibodies 
confirms that the bands corresponding to the size of EZH2 diminish upon EZH2 knockdown 
(Figure 4.1E, bottom panel).  Importantly, the slower migrating band observed in the pT345 
western blot remains unchanged upon EZH2 knockdown indicating that this is cross-reacting 
band while the faster migrating band corresponds to pT345 as this is band decreases upon 
EZH2 knockdown.  Collectively, the above experiments demonstrate the specificity of the 
phospho-EZH2 antibodies as well as the presence of pT345 and pT487 in cells.   
 
Knockdown of EZH2 results in accumulation of cells in G2/M phases 
 To provide insight into possible functional consequences of EZH2 phosphorylation as 
well as putative kinase(s), it was imperative to examine how loss of EZH2 affected cells.  
Consistent with previous studies in U2OS cells (Bracken et al., 2003), knockdown of EZH2 
in HeLa cells resulted to a clear morphological phenotype where cells appeared larger and 
rounder (Figure 4.2A).  Compared to control knockdown cells, EZH2 knockdown cells 
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proliferated significantly slower as shown in Figure 4.2B.  Flow cytometry analysis of DNA 
content indicated that there was a higher percentage of cells in G2/M phase in the EZH2 
knockdown cells compared to the control (Figure 4.2C).  Previous studies have shown that 
knockdown of EZH2 in prostate cells (RWPE) also resulted in the accumulation of cells in 
G2/M (Varambally et al., 2002).  Thus, this data confirms the finding that EZH2 plays a role 
in cell proliferation and extends this observation to HeLa cells. 
 
CDK1 phosphorylates EZH2 at T345 and T487 
To identify a putative kinase responsible for mediating EZH2 phosphorylation at 
T345 and T487, MotifScan and NetPhosK were used identify candidate kinases.  
Interestingly, the cyclin dependent kinase, CDK1 was predicted to be a kinase for both 
phosphorylation sites.  Close inspection of the amino acid residues surrounding both 
phosphorylated threonines revealed the presence of a CDK1-substrate consensus sequence 
(S/T-P-X-R/K) (Figure 4.1A).  As its name suggests, CDK1 requires a cyclin partner for its 
kinase activity.  Specifically, CDK1 associates with cyclin B whose levels peak during 
mitosis.  Given that knockdown of EZH2 results in the accumulation of cells in G2/M phase 
(Figure 4.2C), CDK1 was an attractive candidate for a kinase capable of mediating EZH2 
phosphorylation at T345 and T487.  Thus, I set out to investigate this possibility further. 
To determine whether CDK1 can phosphorylate EZH2 at T345 and T487, a cold in 
vitro kinase assay was performed using purified GST-tagged EZH2 and CDK1-cyclin B 
followed by western blot analysis using the phospho-EZH2 antibodies.  As shown in Figure 
4.3A, phosphorylated EZH2 is only detected when both GST-EZH2 and CDK1-cyclin B are 
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present in the reaction.   Thus, CDK1 is capable of phosphorylating EZH2 at T345 and T487 
in vitro. 
Because in vitro kinase assays may not necessarily mimic in vivo situations, it was 
crucial to determine whether CDK1 contributes to EZH2 phosphorylation in cells.  We took 
advantage of a potent CDK1 inhibitor, roscovitine, and reasoned that inhibition of CDK1 
would lead to a decrease in phosphorylated EZH2.  HEK293T cells exogenously expressing 
Flag-tagged EZH2 were treated with or without roscovitine.  Following Flag 
immunopreciptation, we were able to detect phosphorylated EZH2 in untreated cells (Figure 
4.3B, lane 3).  Importantly, the band corresponding to phosphorylated EZH2 dramatically 
diminishes when cells are treated with roscovitine (Figure 4.3B, compare lane 3 to 4) 
indicating that CDK1 contributes to EZH2 phosphorylation.  Similarly, endogenous phospho-
EZH2 also diminishes when HeLa cells are treated with roscovitine for various times (Figure 
4.3C).  Collectively, this data demonstrates that phosphorylation of EZH2 at T345 and T487 
can be attenuated when CDK1 is inhibited. 
Despite these interesting findings, roscovitine is not only an inhibitor CDK1, but also 
for CDK2 and CDK5 (Meijer et al., 1997) thus necessitating additional evidence to confirm 
that EZH2 is truly a CDK1 substrate.  As discussed above, CDK1 requires association with 
its cyclin partner, cyclin B for its kinase activity.  Cyclin B levels are the highest during late 
G2 and early M phase which correspond to the phases of the cell cycle when CDK1 kinase 
activity peaks.  Thus, if EZH2 is truly a CDK1 substrate, one would expect to observe high 
levels of phospho-EZH2 during mitosis compared to other phases of the cell cycle.  To test 
this hypothesis, HeLa cells were arrested at S phase and M phase by double thymidine block 
and thymidine-nocodazole block respectively.  Western blot analysis using antibodies for the 
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cell cycle markers cyclin B1 (M phase) and SLBP (S phase) confirms that the cells were 
properly arrested (Figure 4.3D).  Importantly, there was an enrichment of phospho-EZH2 in 
the M phase arrested cells was observed when compared to S phase arrested cells.  
Altogether, the above data demonstrates that EZH2 is a CDK1 substrate.   
 
T345 and T487 are not important for global levels of H3K27 tri-methylation 
The previously reported EZH2 phosphorylation site, serine 21 was shown to be 
important for histone methyltransferase activity as phosphorylation of this site caused a 
decrease in its enzymatic activity (Cha et al., 2005).  Thus, it was logical to ask whether 
T345 and T487 are important for the histone methyltransferase activity of EZH2.  There are 
two possible ways in which T345 and T487 may affect the HMT activity of EZH2: (1) they 
may be crucial residues that affect the intrinsic enzymatic activity or (2) they may indirectly 
affect enzymatic activity through disruption of the EZH2 interaction partners, SUZ12 and 
EED.  It should be noted that these two possibilities are not mutually exclusive. 
To address this question, I first asked if mutation of T345 and T487 to alanines 
affected the ability of EZH2 to interact with SUZ12.  NIH3T3 cells stably expressing the 
empty vector (Ctrl), Flag-tagged EZH2 (WT) or T345A/T487A (Mut-A) were generated by 
lentiviral infection.  Immunoprecipitation using Flag antibodies followed by western blot 
analysis using SUZ12 antibodies demonstrates that both WT and Mut-A bound to relatively 
similar amounts of SUZ12 (Figure 4.4A).  Thus, T345 and T487 do not appear to be 
important to maintaining the integrity of the PRC2 complex. 
To assess the contributions of T345 and T487 to EZH2 HMT activity, a dominant 
negative approach was used.  Having established that mutant EZH2 is capable of interacting 
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with Suz12, overexpression of either wildtype or mutant EZH2 was expected to titrate 
SUZ12 and EED from endogenous EZH2.  If T345 and T487 are important residues for 
EZH2 HMT activity, one to expect to observe global decreases of tri-methylated H3K27.  
Using this strategy, Flag-tagged wildtype EZH2, T345A, or T487A were expressed in U2OS 
cells which were immunostained using antibodies against Flag and H3K27me3.  Cells 
transfected with either the T345A or T487A mutant did not exhibit any changes in global 
levels in H3K27 tri-methylation compared to untransfected cells (Figure 4.3B) suggesting 
that these residues do not significantly contribute to EZH2 HMT activity.  Furthermore, 
immunostaining of these cells with Flag antibody revealed that wildtype, T345A, and T487A 
all localized to the nucleus (Figure 4.3B, left panels) indicating that these residues are also 
not important for subcellular localization. 
 
Phosphorylation of EZH2 is important for ubiquitin-mediated degradation 
 In addition to enzymatic function and subcellular localization, phosphorylation can 
also affect the stability of the protein.  Given that both mRNA and protein levels of EZH2 
accumulate at the G1/S phase transition (Bracken et al., 2003), I hypothesized that 
phosphorylation of EZH2 during mitosis functioned as a signal for its destruction.  To assess 
this possibility, the half lives of total EZH2 were compared to that of pT345 and pT487.  
HEK293T cells were transfected with Flag-tagged wildtype EZH2 and treated with the 
protein synthesis inhibitor, cycloheximide for different times.  Western blot analysis using 
the Flag antibody allowed for detection of total exogenous EZH2 which exhibited a half life 
of approximately 2 hours (Figure 4.5A) similar to a previously published study (Dimri et al., 
2010).  On the other hand, pT345 and pT487 exhibited similar half lives (~ 1 hour) that were 
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significantly shorter compared to total EZH2 (Figure 4.5A).  The shorter half life of pT345 
and pT487 may be due to either dephosphorylation of EZH2 or reduced stability of the 
protein.  Previous studies demonstrated that EZH2 is a target for ubiquitination (Dimri et al., 
2010) thus opening the possibility that phosphorylation of EZH2 may regulate its stability. 
To assess whether phosphorylated EZH2 is ubiquitinated, pT345 and pT487 were 
immunoprecipitated from HeLa cells using the phospho-specific antibodies while rabbit IgG 
was used as a negative control.  Western blot analysis of bound proteins was performed using 
antibodies against EZH2, pT345, pT487, and ubiquitin.  As shown in Figure 4.5B, when 
either pT345 or T487 was immunoprecipitated, a ladder of bands reminiscent of poly-
ubiquitinated proteins was observed which supports the notion that phosphorylated EZH2 
serves as a signal for ubiquitin-mediated degradation. 
 To further validate that pT345 and pT487 are important for the destruction of EZH2, 
an in vivo ubiquitination assay was performed in HEK293T cells exogenously expressing 
HA-tagged ubiquitin as well as either the empty vector (Ctrl), Flag-tagged wildtype EZH2 
(WT), T345A/T487A (Mut-A), or T345E/T487E (Mut-E).  This assay specifically takes 
advantage of the fact that ubiquitination is a covalent modification allowing for 
immunoprecipitation under denaturing conditions.  Importantly, denaturing conditions allows 
one to rule out the possibility that interaction partners (which may also be ubiquitinated) are 
not pulled down.  Flag-immunoprecipitated proteins were analyzed by western blot using HA 
antibodies which indicated that WT, Mut-A, and Mut-E were all ubiquitinated to a similar 
degree (Figure 4.5C, lanes 1-4).  Additionally, these cells were also treated with the 
proteasome inhibitor, MG132 to determine whether ubiquitination of EZH2 resulted in 
degradation in a proteasome dependent manner.  Results shown in Figure 4.5C demonstrate 
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that MG132 treatment resulted in the accumulation of WT, Mut-A, and Mut-E ubiquitination 
products and indicates that ubiquitination of EZH2 results in degradation mediated by the 
proteasome. 
 Although the above experiment did not confirm that T345 and T487 are important for 
ubiquitination of EZH2, it should be noted that this experiment was performed in 
asynchronous cells.  Given that phosphorylation of EZH2 occurs during mitosis (Figure 
4.3D) and that mitotic cells account for approximately 10-20% of the total cell population, 
similar levels of ubiquitinated WT and mutant EZH2 observed in the above experiment may 
simply be the consequence of low levels of phosphorylated EZH2 in asynchronous cells.  
Therefore, to circumvent this issue, the in vivo ubiquitination assay was performed using 
HeLa cells stably expressing EZH2.  These cells were first transfected with HA-tagged 
ubiqutin and then arrested at mitosis by thymidine-nocodazole block.  Prior to harvesting, the 
cells were treated with or without MG132.  Although ubiquitinated EZH2 was not detected in 
the untreated cells, wildtype EZH2 was clearly ubiquitinated when cells were treated with 
MG132 (Figure 4.5D, right panel, lane 2). Importantly, mutation of both T345 and T487 to 
either an alanine (Mut-A) or glutamate (Mut-E) dramatically reduced ubiquitination of EZH2 
(Figure 4.5D, right panel, compare lane 2 to lanes 3 and 4).  Interestingly, Mut-E was 
modestly ubiquitinated suggesting this mutation partially acts as a phospho-mimicking 
mutation.  Collectively, the above data demonstrates that phospho-EZH2 is degraded via the 
ubiquitin pathway. 
 
EZH2 T345 and T487 are important for cell proliferation 
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Because EZH2 is important for cell proliferation (Figure 4.2, (Bracken et al., 2003)) 
coupled with the observation that phosphorylation of EZH2 is cell cycle regulated, I was 
interested in determining if T345 and T487 of EZH2 were important for cell proliferation.  
To test this possibility, prostate cancer cells (PC3) and HeLa cells were infected with 
lentiviruses expressing the empty vector (Ctrl), Flag-tagged wildtype EZH2 (WT), or 
T345A/T487A (Mut-A).  Western blot analysis demonstrates that wildtype and mutant EZH2 
were expressed at relatively similar levels (Figure 4.6A and C).  Cell proliferation was 
monitored by absorbance using the MTS assay and the number of cells was calculated using 
a standard curve.  Consistent with previous reports (Bracken et al., 2003), overexpression of 
EZH2 in both PC3 and HeLa cells results in increased cell proliferation compared to cells 
infected with a control lentivirus (Figure 4.6B and D, compare red line to blue line).  
Interestingly, both cell lines expressing Mut-A proliferated significantly slower compared to 
wildtype (Fig. 5B, compare green line to red line).  This data highlights the significance of 
T345 and T487 of EZH2 in the cell proliferation.  
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DISCUSSION 
 
In summary, the data presented above demonstrates that T345 and T487 are bona fide 
EZH2 phosphorylation sites that can be phosphorylated by CDK1.  The phosphorylated form 
of EZH2 is enriched during mitosis, in line with the cell cycle phase in which CDK1 activity 
is high.  Consistent with its shorter half life, phospho-EZH2 is ubiquitinated and degraded by 
the proteasome.  Furthermore, mutation of these two conserved threonines confers a 
proliferative disadvantage in at least two cell types.  Altogether, these findings establish a 
role for T345 and T487 in regulating EZH2 stability, a novel consequence of CDK-mediated 
phosphorylation. 
It generally accepted that the repressive function of EZH2 is facilitated by its ability 
to tri-methylate H3K27.  However, as cells undergo replication, epigenetic marks that 
contribute to cell-type specific gene expression patterns need to be “remembered”.  The 
mechanisms underlying cellular memory are poorly understood although it is evident that 
EZH2 (as well as other Polycomb group proteins) plays a significant role in this process.  
Interestingly, the PRC2 complex can bind to tri-methylated H3K27 and was observed to 
colocalize with this mark during G1 as well as sites of ongoing DNA replication (Hansen et 
al., 2008).  This led to authors to suggest a model where PRC2 binds to established sites of 
H3K27 tri-methylation during DNA replication and transmits the mark to the newly 
synthesized histones incorporated into the daughter strand.  This mechanism is reminiscent of 
how DNA methylation patterns are maintained during cell division (Figure 1.1).  Given the 
amount of epigenetic information that must be transmitted to the daughter strands, one might 
expect to observe upregulation of EZH2 prior to DNA replication.  Consistent with this 
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notion, the pRB-E2F pathway regulates EZH2 transcription and both mRNA and protein 
levels of EZH2 accumulate at the G1 to S transition (Bracken et al., 2003). 
After the cell has successfully replicated its DNA and transmits its epigenetic marks, 
what becomes of the excess EZH2 that was required for this process?  This question is 
particularly relevant given the importance of regulating EZH2 levels as discussed earlier.  
Although EZH2 has a relatively short half life (~2 hours as shown in Figure 4.5A), an 
additional mechanism to ensure that normal EZH2 levels are restored after epigenetic marks 
are transmitted might involve mitotic phosphorylation of EZH2 so that it is targeted for 
degradation (Figure 4.7).  Because EZH2 targets and represses the CDKN2A tumor 
suppressor locus (Agherbi et al., 2009; Bracken et al., 2007; Kotake et al., 2007), degradation 
of excess EZH2 after mitosis may be important to keep cell proliferation in check.   
At the time this work was nearing completion, three studies concerning the 
identification and characterization of pT345 and pT487 were published (Chen et al., 2010; 
Kaneko et al., 2010; Wei et al., 2010).  In line with my data, these reports all demonstrated 
that phosphorylation of these residues is cell cycle regulated and mediated by CDK1.  
Interestingly, various functions of EZH2 phosphorylation were reported and while some 
conclusions were consistent, others were not.   
Chen et al. provided evidence demonstrating that phosphorylation of T350 (the 
human residue correspondings to murine T345) is important for the recruitment of EZH2 and 
maintenance of H3K27 tri-methylation at PRC2 target loci including HOXA9 and DAB2IP.  
This may be explained by the observation that the phospho-mimetic mutant T345E exhibits 
enhanced binding to the lncRNA HOTAIR and XIST which are known to recruit EZH2 to 
target loci (Kaneko et al., 2010).  Collectively, these two studies indicate that T345 
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phosphorylation plays an important role in regulating the recruitment of EZH2 to control 
levels of H3K27 tri-methylation at target promoters. 
On the other hand, Wei et al. reported that phosphorylation at T492 (T487 in mouse 
EZH2) disrupts EZH2 binding with other the PRC2 components SUZ12 and EED thereby 
attenuating EZH2 methyltransferase activity.  However, I observed no difference in SUZ12 
binding when wildtype mouse EZH2 and T345A/T487 double mutant were compared 
(Figure 4.4A).  The authors also observed enhanced EZH2 recruitment when the T492A 
mutant was expressed which coincided with more H3K27 tri-methylation at the promoters of 
target genes, HOXA7 and HOXA9.  On the contrary, I did not observe any changes in global 
levels of H3K27 tri-methylation (Figure 4.4B) which does not preclude the possibility that 
H3K27 tri-methylation is affected by EZH2 phosphorylation at target promoters.  However, 
Kaneko et al. reported that T487 phosphorylation does not affect the HMTase activity of 
PRC2.  While these discrepancies might be attributed to differences between human and 
mouse EZH2, this possibility is unlikely given the high conservation of the PRC2 complex 
and the EZH2 T487 phosphorylation site.  Hence, further work is necessary to sort out the 
differences between these studies.   
A role for T350 phosphorylation in regulating EZH2 protein stability was also 
investigated by Chen et al., but the authors concluded that it had no effect.  However, the 
basis of this conclusion stemmed from an experiment where the half lives of wildtype and 
T350A EZH2 were compared and found to be similar.  I also initially compared the half lives 
of wildtype and T345A mouse EZH2 and came to the same conclusion (data not shown).  
However, phosphorylation of T345 occurs during mitosis (Figure 4.3D and (Kaneko et al., 
2010) and it was estimated that in asynchronous cells, only 1% of EZH2 is phosphorylated at 
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T345 (Kaneko et al., 2010).  For this reason, I further examined a role for EZH2 
phosphorylation in regulating protein stability by comparing the half life of total EZH2 to 
pT345 (using the phospho-specific antibodies I generated).  Although I can not rule out that 
the shorter half life of EZH2 is due to dephosphorylation, the notion that phosphorylation of 
EZH2 regulates its stability is supported by the observation that EZH2 is ubiquitinated which 
is impaired in the T345A/T487A mutant (Figure 4.5B and C). 
At first glance, it may seem contradictory that phosphorylation of T345 leads to 
EZH2 instability given that this modification is also important for binding of EZH2 to 
lncRNAs to facilitate recruitment to target promoters (Kaneko et al., 2010).  However, it 
should be noted that these two consequences of T345 phosphorylation are not necessarily 
mutually exclusive.  Since pT345 constitutes a small fraction of total EZH2, Kaneko et al 
suggest that this form of EZH2 may important for the initial establishment of the tri-
methylated H3K27 mark.  This mark can later be propagated by other PRC2 complexes 
regardless of their EZH2 phosphorylation status especially since PRC2 can bind to tri-
methylated H3K27 (Hansen et al., 2008).  Thus, EZH2 pT345 may be degraded after 
lncRNAs facilitate their recruitment and H3K27 tri-methylation marks are established 
(Figure 4.7).  Given that we presently do not know the kinetics of EZH2 recruitment, we can 
not confirm or deny this possibility.  However, this model is particularly attractive because 
the initial recruitment of EZH2 may be more specific given the use of lncRNAs. 
Collectively, these studies show that T345 and T487 phosphorylation may have 
distinct functions.  T345 phosphorylation regulates the recruitment of EZH2 to target loci 
(Chen et al., 2010; Kaneko et al., 2010) whereas phosphorylation of T492 in human EZH2 
can affect SUZ12 binding to modulate HMT activity (Wei et al., 2010).  Interestingly, 
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phosphorylation of these residues can occur at the simultaneously as shown in Figure 4.5B.  
Although the half lives of pT345 and pT487 are indistinguishable (Figure 4.5A) which 
suggest that they may function similarly, a systemic study will be required to dissect their 
individual contributions and discern the relationship between these two phosphorylation 
sites. 
Expression of human T350A, but not T492A resulted in slower cell proliferation 
(Chen et al., 2010; Wei et al., 2010) suggesting that proliferative disadvantage I observed in 
cells expressing both mouse T345A and T487A was due to loss of phosphorylation of T345, 
but not T487.  Interestingly, cancer cell migration and invasion was dependent on 
phosphorylation of T350 (Chen et al., 2010), but was enhanced when the phospho-deficient 
mutant T492A was expressed (Wei et al., 2010) suggesting that pT492 inhibited these 
biological functions.  Based on these two observations, pT350 and pT487 appear to play 
opposing roles in cancer cell migration and invasion.  Given that these two phosphorylation 
sites can exist simulateneously within mouse EZH2 (Figure 4.5B), it will be important to 
determine which of these modifications dominates by examining migration and invasion of 
cells expressing the double mutant T345A and T487A. 
In summary, the findings described in this chapter coupled with those by other groups 
demonstrate an important role for CDK1-mediated phosphorylated of EZH2.  Like EZH2, 
CDK1 activity is positively associated with cell proliferation and cancer (Malumbres and 
Barbacid, 2009) and has emerged as a central player in controlling ES cell self-renewal and 
lineage specification (Van Hoof et al., 2009).  Thus, this mechanism of EZH2 regulation may 
provide valuable insight into the development of therapeutic drugs as well as methods in 
regenerative medicine. 
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EXPERIMENTAL PROCEDURES 
 
Cell culture, transfections, and drug treatments.  HEK293T, HeLa, U2OS, and NIH3T3 
cells were cultured in Dulbecco’s modified eagle medium (DMEM) supplemented with 10% 
fetal bovine serum and penicillin/streptomycin.  PC3 cells were cultured in DMEM/F12 (1:1) 
media supplemented with 10% fetal bovine serum and penicillin/streptomycin.  Transfections 
were performed using Lipofectamine 2000 (Invitrogen cat# 11668-019) or FuGENE 6 
(Roche cat# 11814443001).  Roscovitine was purchased from Cell Signaling Technology 
(cat# 9805) and used at a final concentration of 50 µM.  Cycloheximide (Sigma cat# C4859) 
was used as a final concentration of 100 µg/mL. 
 
Expression plasmids.  Mouse EZH2 was inserted into the mammalian expression vector, 
pcDNA3-Flag as previously described in Chapter 3.  Site-directed mutagenesis was 
performed using the Stratagene QuikChange II XL kit (Agilent cat# 200521) and 
mutagenesis primers listed in Table 4.1.  For bacterial expression, EZH2 was subcloned into 
pGEX-KG with an N-terminal GST tag.   All EZH2 constructs were verified by sequencing 
using the primers listed in Table 3.3 of Chapter 3.  pCMV-(HA-Ubiquitin)x4 was a kind gift 
from the laboratory of Dr. Yue Xiong and has been previously described (Furukawa et al., 
2005). 
 
Lentiviral production.  Wildtype EZH2, T345A/T487A, and T345E/T487E were cloned 
into the lentiviral vector pTYF under the control of the EF1α promoter.  For knockdown 
experiments, shRNAs targeting human EZH2 as well as a control shRNA were cloned into 
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pTYF under the control of the U6 promoter.  The targeted sequences are as follows: Control 
(5’ GTTCAGATGTGCGGCGAGT 3’), EZH2 KD (5’ GCTGCCTTAGCTTCAGGAA 3’).  
The lentiviral system used has been described previously (He et al., 2008). 
 
Antibodies.  The following antibodies were used in this study: Flag M2 mouse monoclonal 
(Sigma cat# F3165), rabbit EZH2 (Cell Signaling cat# 4905), rabbit SLBP (gift from William 
Marzluff, UNC), mouse cyclin B1 (Santa Cruz), mouse α-tubulin (Sigma cat# T6199), 
mouse GST (Santa Cruz cat# sc-138), rabbit H3K27me3 (Millipore cat# 07-449), rabbit 
Suz12 (REF).  Antibodies against phospho-EZH2 pT345 and pT487 are described below. 
 
Production and affinity purification of pT345 and pT487 antibodies.  Antibodies against 
pT345 and pT487 were produced by injecting KLH-conjugated phosphorylated peptides into 
rabbits using a standard protocol outlined by Pocono Rabbit Farm & Lab (Canadensis, PA).  
The sequences of peptides used are as follows: pT345 (CTAERIKTPPKRPG-NH2) and 
pT487 (Ac-CPTEDVD(pT)PPRKK).  Serum from the rabbits was collected on a weekly 
basis and production of antibodies was monitored by dot blot analsyis (see below).  
Unmodified or phosphorylated peptides were individually conjugated to AffiGel 10 for 
pT345 or AffiGel 15 for pT487 (BioRad cat# 153-6046 and 153-6052).  Briefly, 1 mL of 
AffiGel (50% slurry) was washed in ice cold PBS and conjugated with 1 mg of peptide at 
4°C for 2 hours.  The resin was then transferred to a mini-column and washed once with 10 
mL of 0.2 M ethanolamine (pH 8.0).  To block the resin, 10 mL of 0.2 M ethanolamine (pH 
8.0) was added to the plugged column which was rotated at 4°C for 2 hours.   The resin was 
then washed once with 1M NaCl and then twice with 10 mL of ice cold PBS to lower the salt 
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concentration.  To remove antibodies recognizing pan- and unphosphorylated EZH2, 10 mL 
of the serum was first incubated with the unphosphorylated peptide column and rotated 
overnight at 4°C.  The flow through was then incubated to the phosphorylated peptide 
column and rotated overnight at 4°C.  The column was then washed with 0.5 M NaCl until 
no protein could be detected by the Bradford assay (BioRad Protein Assay cat# 500-0006) 
where 100 µL of reagent was used for one drop from the column.  The salt concentration was 
reduced by washing the column two times with ice cold PBS.  To elute the antibody, 200 µL 
of 0.1 M glycine (pH 3.0) was added to the column.  Each elution was monitored by the 
Bradford assay (using 100 µL of reagent and 4 µL of elution) and those containing similar 
concentrations of antibody were pooled together.  Each pool was adjusted so that it contained 
a final concentration of 100 mM Tris (pH 8.0), 50 mM NaCl, and 10% glycerol.  The final 
antibody was analyzed and quantified by SDS-PAGE.   
 
Dot blot analysis.  To validate the serum or phospho-specific antibodies, two-fold dilutions 
of both the unmodified and phosphorylated peptides were spotted on a PVDF membrane 
assembled in a dot blot apparatus with filter paper.  A total of 100 µL was spotted and the 
series began with 1 mg of peptide.  PBS was used as a negative control.  After applying a 
vacuum source, the PVDF membrane was subjected to Western blot analysis as described 
below.  Both pre- and post-injection serums were used at a 1:1000 dilution.  Affinity-purified 
antibodies against pT345 and pT487 were used at a concentration of 16 ng/mL and 40 
ng/mL.  
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Cell extract preparation and immunoprecipitation. Cell pellets were resuspended with 
RIPA lysis buffer consisting of 50 mM Tris (pH 7.4), 1% NP-40, and 150 mM NaCl 
supplemented with protease and phosphatase inhibitors (Roche Complete Protease Inhibitors 
cat# 11697498001 and Roche PhosSTOP cat# 04906837001).  Lysates were incubated on ice 
for 45 minutes and subjected to centrifugation at 17000 x g for 15 minutes at 4°C.  The 
resulting supernatant was transferred to a new tube and the protein concentration of the lysate 
was determined by Bradford assay (BioRad Protein Assay cat# 500-0006).  For Flag 
immunoprecipitations, 30 µL of α-Flag M2 affinity gel (Sigma cat# A2220) was added to the 
lysates and rotated at 4°C overnight.  Bound proteins were washed 3 times with the RIPA 
lysis buffer prior to the addition of 2X SDS loading buffer.  Bound proteins were then 
resolved by SDS-PAGE. 
 
Subcellular fractionation.  For HeLa cytosolic extracts, nuclear extracts, and nuclear pellet, 
fractions prepared previously were used (Cao et al., 2002; Wang et al., 2004).  To prepare 
subcellular fractionation for NIH3T3 cells, the cell pellet was resuspended in lysis buffer A 
(10 mM Tris, pH 8.0, 140 mM NaCl, 1.5 mM MgCl2, and 0.5% NP-40) supplemented with 
protease and phosphatase inhibitors followed by incubation on ice for 5 minutes.  Nuclei 
were centrifuged at 1000 x g for 3 minutes at 4°C.  The supernatant containing the cytosolic 
fraction was transferred.  The pellet was resuspended in the same volume of RIPA lysis 
buffer containing protease and phosphatase inhibitors.  After a 30 minute incubation on ice, 
the insoluble material was centrifuged at 17000 xg for 15 minutes at 4°C.  The supernatant 
containing the nuclear extract was transferred and both extracts were subjected to the 
Bradford assay to determine the protein concentration. 
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Western blot analysis.  Proteins resolved by SDS-PAGE were transferred onto 
nitrocellulose membranes (BioRad cat# 162-0112).  Blots were blocked with 5% nonfat milk 
in TBST (50mM Tris, pH 7.4, 150 mM NaCl, 0.05% Tween) for 1 hour at room temperature 
followed by a quick rinse with TBST.  Primary antibodies were diluted in TBST and added 
to the blots for overnight incubation at 4°C.  Following a quick TBST rinse, secondary 
antibodies diluted in TBST were added.  Blots were washed 3 times with TBST prior to 
chemiluminescence detection (ECL Western blotting substrate, Pierce cat# 32106).  When 
applicable, blots were stripped using RestoreTM Plus Western Blot Stripping Buffer (Pierce 
cat# 46428).  For quantification of bands, ImageJ (National Institutes of Health) was used.   
 
Immunostaining.  Cells grown on glass coverslips were washed once with PBS and fixed 
with 4% paraformaldehyde in PBS for 20 minutes.  Coverslips were washed twice in PBS 
and cells were permeablised with 0.5% Triton-X-100 in PBS for 10 minutes.  After two 
washes with PBS, coverslips were blocked with 3% BSA, 10% donkey serum, and 1% Triton 
X-100 in PBS for 30 minutes followed by another two PBS washes.  Primary antibodies were 
diluted in the blocking solution diluted 10 fold in 0.1% Triton X-100 in PBS and spotted on 
parafilm.  Coverslips were placed faced down on the antibody and incubated at room 
temperature for 1 hour followed by 4 washes with PBS for 3 minutes each.  Secondary 
antibodies were diluted in the same way as the primary antibody and coverslips were 
incubated with the secondary antibody for 45 minutes in the dark.  After washing the 
coverslips with PBS four times (3 minutes per wash), the coverslips were counterstained with 
Hoechst and then mounted on a glass microscope slide.   
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RT-quantitative PCR.  Total RNA was extracted using the RNeasy kit (Qiagen cat# 74104) 
and treated with DNaseI (Promega cat# M610A) as outlined by the manufacturers’ protocols.  
Reverse transcription was carried out using Superscript II (Invitrogen cat# 18064-022).  The 
resulting cDNA was used for Real Time PCR analysis on an Applied Biosystems 7300 Real 
Time PCR machine using SYBR GreenER (Invitrogen cat# 11762-500). 
 
Protein purification.  Purified recombinant PRC2 complex is described elsewhere (Cao and 
Zhang, 2004a).  GST-EZH2 was produced by Escherichia coli BL21 cells which were 
induced at OD600 of 0.5 by the addition of 0.2 mM IPTG for 30 hours at 16°C.  Cells were 
pelleted and resuspended in GST lysis buffer (20 mM Tris, pH 8.0, 500 mM NaCl, and 0.1% 
NP-40) supplemented with protease inhibitors.  The suspension was sonicated on ice using a 
Branson Digital Sonifier at 30% amplitude for 3 minutes using with cycles of 0.3 seconds on 
and 0.3 seconds off.  This was repeated 6 times with 3 minute incubations on ice in between 
each sonication.  The lysate was then centrifuged at 12500 rpm for 20 minutes at 4°C.  After 
transferring the supernatant, 500 µL of GST beads (Amersham cat# 17-5131-01) were added 
to the clarified lysate and rotated for 1 hour at 4°C.  Bound proteins were washed 3 times 
with BC100 (40 mM Hepes, pH 7.9, 0.2 mM EDTA, 100 mM KCl, 10% glycerol, 1 mM 
DTT, and 0.2 mM PMSF) and transferred to a 1.5 mL eppendorf tube.  To sequentially elute 
the bound proteins, 500 µL of BC100 containing 10 mM glutathione was added and the tube 
was rotated for 5 minutes at 4°C.  This was repeated until no protein could be detected by 
Bradford assay.  Elutions were pooled and dialyzed against BC100 overnight at 4°C.   
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In vitro kinase assay.  Recombinant GST-EZH2 was incubated with CDK1-cyclin B (NEB 
cat# P6020) in the presence of 1 mM cold ATP for 30 minutes at 30°C.  The reaction was 
terminated by the addition of 5X SDS loading buffer.  Reaction products were analyzed by 
western blot analysis.   
 
Cell cycle synchronization.  HeLa cells arrested at S phase were obtained through a double-
thymidine block, while M phase arrested cells were collected after a thymidine-nocodazole 
block.  In short, cells were first treated with 1 mM thymidine for 18 hours.  Cells were 
washed 2 times with PBS and released for 4 hours (M) or 8 hours (S) prior to a second block 
with 1 mM thymidine (S) or 0.1 µg/mL nocodazole (M) for 16 hours.  S phase arrested cells 
were collected by trypsinization, while M phase arrested cells were collected by pipetting 
cells off the dish. 
 
In vivo ubiquitination assay.  Cell pellets were resuspended in pre-boiled SDS-lysis buffer 
(50 mM Tris, pH 7.5, 0.5 mM EDTA, 1% SDS, 1 mM DTT) and further boiled for an 
additional 10 minutes.  Lysates were clarified by centrifugation at 17000 x g for 10 minutes 
at 4°C.  The supernatant was transferred to a new tube and protein concentration was 
measured by Lowry Assay (BioRad DC Protein Assay cat# 500-0112).  For 
immunoprecipitations, the lysates was first diluted 10-fold with RIPA lysis buffer and 
incubated with 20 µL of α-Flag M2 affinity gel (Sigma cat# A2220) overnight at 4°C.  
Bound proteins were washed 3 times with RIPA lysis buffer and eluted with 2X SDS loading 
buffer. 
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Cell proliferation assay.  For Figure 4.2B, cell proliferation was monitored using trypan 
blue and a hemocytometer.  For Figure 4.6, cell proliferation was monitored by absorbance 
using the MTS assay (CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega 
cat# G3582).  Approximately 5000 cells per well were seeded in triplicate in a 96 well plate.  
At the indicated times, 20 µL of the reagent was added to the cells and incubated at 37°C for 
1.5 hours.  Absorbance at 490 nm was measured in a microplate reader.  Following 
background subtraction, the number of cells was back calculated using an established 
standard curve.  The number of cells at day 0 was set to 1.   
 
Flow cytometry for DNA content.  One million cells were harvested and washed twice with 
ice cold PBS.  Cell pellets were resuspended with 500 uL ice cold PBS and fixed by the 
addition of 4.5 mL ice cold 70% ethanol.  To stain cells, one wash with PBS was performed 
and the cell pellet was resuspended with 250 µL of PBS and 750 µL of the propidium iodide 
staining mix (40 µg/mL propidium iodide, 100 µg/mL RNase A, 0.1% Triton X-100 in PBS).  
Cells were stained for 15 minutes at 37°C and analyzed for DNA content using the Beckman-
Coulter (Dako) CyAn ADP flow cytometer.
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Figure 4.1 EZH2 is phosphorylated at threonines 345 and 487.   
(A) Threonines 345 and 487 are conserved across species.  Human, mouse, zebrafish, and fly 
EZH2 were aligned using MultAlin.  Relevant regions are shown.  Threonines 345 and 487 
are highlighted in red, while conserved amino acids are highlighted in blue. 
 
(B) Specificity of the phospho-EZH2 antibodies.  Dot blot analysis was performed using 2-
fold dilutions of the unmodified and phosphorylated peptides corresponding to amino acids 
surrounding T345 or T487.   
 
(C) Exogenously expressed EZH2 is phosphorylated at T345 and T487.  HEK293T cells 
were transfected with empty vector, Flag-tagged wildtype EZH2, and Flag-tagged mutants.  
Following Flag immunoprecipitation, bound proteins were analyzed by western blot analysis 
using the indicated antibodies.   
 
(D) Endogenous EZH2 is phosphorylated at T345 and T487.  Western blot analysis of 
NIH3T3 and HeLa cell extracts using the phospho-EZH2 antibodies.  For NIH3T3 extracts, 
100 µg of nuclear extract and the equivalent volume of cytoplasmic extract were loaded.  For 
HeLa extracts, 100 µg of each fraction was loaded.  Recombinant PRC2 complex was used 
as a positive control.  CYT: cytoplasmic; NE: nuclear extract; NP: nuclear pellet.   
 
(E) Knockdown of EZH2 results in decreased levels of phospho-EZH2.  HeLa cells were 
infected with lentiviruses expressing either control shRNA or EZH2 shRNA.  Top panel: RT-
qPCR confirming EZH2 knockdown.  Bottom panel: Lysates were subjected to western blot 
analysis using the indicated antibodies. 
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Figure 4.1 (continued) 
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Figure 4.2 Knockdown of EZH2 results in slow growth and accumulation of cells  
in G2/M. 
 
(A) EZH2 knockdown results in larger and rounder cells.  Brightfield images of HeLa cells 
stably expressing control shRNAs or EZH2 shRNAs. 
 
(B) Cell proliferation defect in EZH2 knockdown cells.  100000 cells were seeded and cell 
proliferation was monitored by trypan blue using a hemocytometer for 4 days. 
 
(C) Knockdown of EZH2 results in an accumulation of cells in G2/M.  The cell cycle 
profiles of control and EZH2 knockdown HeLa cells were analyzed by flow cytometry using 
propidium iodide staining for DNA content. 
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Figure 4.3 CDK1 phosphorylates EZH2 at T345 and T487.  
(A) CDK1 in vitro kinase assay.  Recombinant GST-tagged EZH2 was subjected to a cold 
kinase assay using CDK1-cyclin B kinase.  Western blot analysis using phospho-EZH2 
antibodies confirms that CDK1 phosphorylates GST-EZH2 at both T345 and T487.   
 
(B) Inhibition of CDK1 results in loss of exogenous phospho-EZH2.  HEK293T cells were 
transfected with empty vector or Flag-tagged EZH2.  24 hours post-transfection, cells were 
treated with 50 µM roscovitine (Ros) for 24 hours to inhibit CDK1.  Following Flag 
immunoprecipitation, bound proteins were subjected to western blot analysis using the 
indicated antibodies.   
 
(C) Inhibition of CDK1 results in loss of endogenous phospho-EZH2.  HeLa cells were 
treated with 50 µM roscovitine for the indicated times.  Lysates were analyzed by western 
blot analysis using the indicated antibodies.   
 
(D) Phospho-EZH2 is enriched in cells arrested at mitosis.  HeLa cells were arrested at S 
phase and M phase by double thymidine block and thymidine-nocodazole block respectively.  
Extracts were analyzed by western blot using the indicated antibodies.  SLBP: S phase 
control; cyclin B1: M phase control; tubulin: loading control. 
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Figure 4.3 (continued) 
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Figure 4.4 EZH2 T345 and T487 are not important for global levels of H3K27  
tri-methylation.   
 
(A) T345 and T487 are not crucial for EZH2 binding to Suz12.  NIH3T3 cells stably 
expressing Flag-tagged EZH2 were generated by lentiviral infection.  The interaction 
between EZH2 and Suz12 was tested by Flag-immuopreciptation followed by western blot 
analysis using Suz12 antibodies. 
 
(B) Expression of T345A or T487A mutants does not alter global levels of H3K27me3.  A 
dominant negative approach was used by transfecting Flag-tagged wildtype EZH2, T345A, 
and T487A mutants into U2OS cells.  Immunofluorescence with antibodies against Flag (left 
panels) and H3K27me3 (middle panels) was performed to examine global levels of 
H3K27me3 when EZH2 mutants are expressed.  Nuclei were detected by Hoechst staining 
(right panels).  Yellow arrows point to transfected cells. 
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Figure 4.5  Phosphorylated EZH2 is ubiquitinated and degraded via the proteasome 
pathway. 
 
(A) Phospho-EZH2 exhibits a shorter half life compared to total EZH2.  HEK293T cells 
were transfected with Flag-tagged EZH2 and treated with 100 µg/mL cycloheximide for the 
times indicated.  Western blot analysis was performed using the indicated antibodies (top 
panel).  Bands were quantified using ImageJ (bottom panel). 
 
(B) Phopho-EZH2 is ubiquitinated.  Phospho-EZH2 was immunopreciptated from HeLa 
extracts using antibodies against pT345 and pT487.  Western blot analysis of bound proteins 
was performed using the antibodies indicated. 
 
(C) Ubiquitin status of EZH2 in asynchronous cells.  HEK293T cells were transfected with 
HA-tagged ubiquitin and empty vector (Ctrl), Flag-tagged wildtype EZH2 (WT), 
T345A/T487A (Mut-A), or T345E/T487E (MutE) and treated with or without 25 µM MG132 
for 4 hours.  Lysates were prepared under denaturing conditions and subjected to 
immunoprecipitation using Flag antibodies.  Bound proteins were analyzed by western blot 
using the indicated antibodies. 
 
(D) Ubiquitin status of EZH2 in mitotic cells.  HeLa cells stably expressing empty vector 
(Ctrl), Flag-tagged wildtype EZH2 (WT), T345A/T487A (Mut-A), and T345E/T487E (Mut-
E) were generated by lentiviral infection and transfected with HA-tagged ubiquitin.  Cells 
were synchronized and arrested at mitosis by thymidine-nocodazole block.  Four hours prior 
to harvesting, cells were treated with or without 25 µM MG132.  Lysates were prepared 
under denaturing conditions and subjected to immunoprecipitation using Flag antibodies.  
Bound proteins were analyzed by western blot using the indicated antibodies. 
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Figure 4.5 (continued) 
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Figure 4.6 EZH2 T345 and T487 are important for cell proliferation.   
(A) Western blot analysis confirming that wildtype and T345/T487A mutant are expressed at 
similar levels.  PC3 cells were infected with lentiviruses overexpressing empty vector (Ctrl) 
wildtype EZH2 (WT) or T345A/T487A (Mut-A).  Exogenous EZH2 was detected using Flag 
antibodies while tubulin served as a loading control.   
 
(B) PC3 cells expressing T345A/T487A proliferate slower compared to wildtype.  
Approximately 5000 cells were seeded in triplicate in a 96 well plate and cell proliferation 
was monitored by absorbance using the MTS assay at the indicated times.  The measured 
absorbance was converted to the number of cells using a standard curve.  For each cell line, 
the number of cells at day 0 was set to 1. 
 
(C) Western blot analysis confirming that wildtype and T345/T487A mutant are expressed at 
similar levels.  HeLa cells were infected with lentiviruses overexpressing empty vector (Ctrl) 
wildtype EZH2 (WT) or T345A/T487A (Mut-A).  Exogenous EZH2 was detected using Flag 
antibodies while tubulin served as a loading control.   
 
(D) HeLa cells expressing T345A/T487A proliferate slower compared to wildtype.  
Approximately 5000 cells were seeded in triplicate in a 96 well plate and cell proliferation 
was monitored by absorbance using the MTS assay at the indicated times.  The measured 
absorbance was converted to the number of cells using a standard curve.  For each cell line, 
the number of cells at day 0 was set to 1. 
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Figure 4.6 (continued) 
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Figure 4.7 A model depicting the role of EZH2 phosphorylation during mitosis.   
 
During mitosis when CDK1 kinase activity is high, EZH2 is phosphorylated at T345 and 
T487 (Box 1).  Phosphorylation of T345 facilitates EZH2 interaction with lncRNAs 
including HOTAIR (Box 2) which recruits PRC2 (other components not shown) to Polycomb 
target genes.  Initial H3K27me3 marks are placed on the newly incorporated histones of the 
daughter strand by PRC2 containing phospho-EZH2 (Box 3).  Phosphorylated EZH2 is then 
ubiquitinated and degraded via the proteasome while additional PRC2 complexes (regardless 
of their EZH2 phosphorylation status) bind to the initial tri-methyl H3K27 mark and 
propagate the mark (Box 4).   
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Table 4.1 Mutagenesis primers used in Chapter 4. 
 
Primer Forward Primer Reverse Primer 
T345A CTGAGCGTATAAAGGCACCACCTAAACGCCC 
GGGCGTTTAGGTGGTGCCTTTATACGCTC
AG 
T345E TTACTGCTGAGCGTATAAAGGAGCCACCTAAACGCCCAGGGG 
CCCCTGGGCGTTTAGGTGGCTCCTTTATAC
GCTCAGCAGTAA 
T487A ACTGAGGATGTAGACGCTCCTCCAAGAAAGAAG 
CTTCTTTCTTGGAGGAGCGTCTACATCCTC
AGT 
T487E GTTCCCACTGAGGATGTAGACGAGCCTCCAAGAAAGAAGAAAAGG 
CCTTTTCTTCTTTCTTGGAGGCTCGTCTAC
ATCCTCAGTGGGAAC 
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SUMMARY AND CONCLUDING STATEMENTS 
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In summary, this dissertation describes two novel findings regarding EZH2 (Enhancer 
of zeste 2), the H3K27 histone methyltransferase (HMT) component of PRC2 (Polycomb 
repressive complex 2).  The first observation is that EZH2 not only regulates protein-coding 
genes, but also serves to repress the transcription of lncRNAs (long non-coding RNAs).  This 
finding may not be entirely surprising given that is unlikely that chromatin-modifying 
enzymes have the capacity recognize the difference between a protein coding gene versus a 
non-protein coding gene.  However, since PRC2 complexes can bind to a large number 
lncRNAs (Khalil et al., 2009), the notion that EZH2 can regulate lncRNA expression 
introduces the possibility of regulatory feedback loops.  The second major finding described 
in this work is that EZH2 is a phosphoprotein that can be modified at threonines 345 and 487 
by the cyclin dependent kinase, CDK1.  Importantly, these modifications affect the stability 
of EZH2 and present a novel mechanism by which EZH2 function can be regulated. 
 
EPIGENETIC REGULATION OF LONG NON-CODING RNAS 
 The vast majority of transcription that occurs in the cell results in the production of 
lncRNAs (Kapranov et al., 2007) that are greater than 200 nucleotides in length.  Once 
considered to be transcriptional “junk”, lncRNAs are beginning to emerge as important 
players in diverse biological processes including X-inactivation, imprinting, and HOX gene 
regulation (Nagano et al., 2008; Ponting et al., 2009; Rinn et al., 2007; Wilusz et al., 2009; 
Zhao et al., 2008).  Given that the genomes of humans and worms encode for a relatively 
similar number of genes (He et al., 2007), it is hypothesized that lncRNAs are functional and 
contribute to the complexity of humans.  One key observation in support of lncRNAs as 
functional molecules is that many exhibit cell-type specific expression patterns (Figure 2.1B 
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and C; (Dinger et al., 2008; Mercer et al., 2008; Ravasi et al., 2006)).  This observation 
suggests that like protein-coding genes, lncRNAs are epigenetically regulated.   
 To investigate this possibility, lncRNAs curated in the FANTOM3 database were 
used for the study described in Chapter 2.  Given that lncRNAs may be indirectly regulated 
based on their location within the same transcriptional unit of a protein-coding gene, Eric 
Kallin focused on the subset that exhibited no overlap with the promoter (as defined as -1kb 
to 1kb surrounding the transcription start site) or the coding region of annotated genes.  
Analysis of epigenetic modifications at lncRNA promoters was performed using previously 
published genome-wide maps of relevant histone modifications (Mikkelsen et al., 2007) and 
revealed that lncRNAs exhibit distinct patterns of H3K4 and H3K27 tri-methylation that was 
dependent on the cell type (Figure 2.2).  The presence of these epigenetic marks at lncRNA 
promoters correlated with their expression patterns in ES cells, neuroprogenitor cells, and tail 
tip fibroblasts (Figure 2.3).  Importantly, I demonstrate in Figure 2.4 that EZH2 contributes 
to the repression of lncRNAs in ES cells as shRNA-mediated knockdown of EZH2 resulted 
in their derepression.  Collectively, these findings highlight a novel function for EZH2. 
 What might be the significance of EZH2-mediated repression of lncRNAs?  As 
mentioned above, PRC2 binds to a large number of lncRNAs (Khalil et al., 2009) and thus 
repression of lncRNAs may function to negatively regulate their association with PRC2.  
Future work will be required to determine whether PRC2-associated lncRNAs are also 
targets for EZH2 repression.  At first glance, this may appear to be a simple and quick 
analysis to perform.  However, the lncRNAs regulated by EZH2 identified in Chapter 2 are 
mouse while PRC2-associated lncRNAs identified by Khalil et al. are human which 
introduces the issues of lncRNA conservation across species.  Compared to protein-coding 
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genes, lncRNAs appear to be less evolutionarily constrained (Mercer et al., 2009) and it is 
difficult to assign conservation on the basis of sequence, particularly because different 
nucleotide sequences may confer similar secondary structures.  Furthermore, many lncRNAs 
such as XIST exhibit high conservation only in short stretches across the entire RNA (Pang 
et al., 2006).   
With respect to protein-coding genes, it is well established that EZH2 targets include 
a large number of developmental regulators including those involved in ES cell 
differentiation (Boyer et al., 2006).  Extending on this observation, it is likely that lncRNAs 
repressed by EZH2 in ES cells also play important roles in differentiation.  Expression 
profiling of lncRNAs coupled with genome-wide maps of histone modifications (as 
performed in Chapter 2) provides a powerful way to identify candidates that may be 
important during ES cell differentiation.  Specifically, these candidates are expected to 
exhibit the following epigenetic and expression patterns which would be consistent with an 
important role in ES cell differentiation:  (1) bivalent modification (both H3K4 and H3K27 
tri-methylation) and low expression in ES cells and (2) H3K4 tri-methylation and high 
expression in neuroprogenitors and/or fibroblasts.  To determine whether these candidates are 
important for ES differentiation, shRNA-mediated knockdown of these lncRNAs followed 
by phenotypic tests may be performed.  These types of analyses include but are not limited to 
alkaline phosphatase staining (which is a marker for ES cells), ability to form embryoid 
bodies as defined by morphology when differentiation is induced, and RT-qPCR analysis of 
lineage-specific markers. 
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LONG NON-CODING RNAS AND ES CELL BIOLOGY 
 In contrast to the studies proposed above, it may be of greater interest to identify 
lncRNAs that are important for ES cell identity.  As described in the Introduction (in the 
section titled “ES cell pluripotency, self-renewal, and differentiation”), studies involving ES 
cells where components of the PRC2 complex have been deleted, suggested that loss of the 
ES cell state requires repression of pluripotency factors as this event appears to be more 
important than the upregulation of lineage-specific genes during ES cell differentiation.  
There is great interest in identifying factors important for pluripotency given their 
implications in regenerative medicine.  Sustained expression of a cocktail of pluripotency 
factors, OCT4, SOX2, KLF4, and c-MYC can induce somatic cells to dedifferentiate back to 
an ES cell-like state (Takahashi and Yamanaka, 2006).  The slow kinetics and low efficiency 
of this process have led many groups to pursue identification of additional factors that can 
improve this method.  Protein factors are currently receiving all the attention which does not 
imply that lncRNAs do not contribute to this process.   
 In an effort to identify such lncRNA factors, Eric Kallin and I identified ten 
candidates which exhibited H3K4 tri-methylation and high expression in ES cells coupled 
with H3K27 tri-methylation and low expression in neuroprogenitor cells and fibroblasts.  
Lentiviruses expressing three independent shRNAs targeting each of the ten lncRNAs were 
generated and used to infect ES cells.  Unfortunately, knockdown of these candidate 
lncRNAs did not result in changes in ES cell identity characterized by alkaline phosphatase 
staining (data not shown).  Although this approach was initially unsuccessful, other candidate 
lncRNAs can certainly be tested. 
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INVESTIGATING THE FUNCTION OF LONG NON-CODING RNAS 
 Although analysis of the mammalian transcriptome has led to the identification of 
thousands of lncRNAs, one of the biggest challenges in the field of lncRNAs is defining their 
function.  In contrast to microRNAs and proteins, the function of lncRNAs can not be 
predicted from their sequence at the present time.  Furthermore, structural predictions are 
computationally demanding given the length of many of these lncRNAs.  Functional roles 
reported for lncRNAs so far are few and diverse and therefore, it is difficult to make any 
simple generalization regarding their function. 
 While some information can be gained by studying the cell-type expression pattern 
and sub-cellular localization of a lncRNA, determining their functional role on the basis of 
this information is an extremely difficult endeavor.  Given that at least one fifth of all 
lncRNAs identified so far can associate with PRC2 (Khalil et al., 2009), identifying protein 
interaction partners of lncRNAs may provide more insight into their function.  A biochemical 
approach can easily be employed where the lncRNA of interest is in vitro transcribed and 
biotinylated followed by streptavidin pulldown from cell extracts.   
  Although tedious and laborious, the only way to decipher the functional role of 
lncRNAs is to characterize each one individually.  Structure-function studies will 
undoubtedly be useful in helping to progress our knowledge regarding lncRNAs.  Once a 
large number of lncRNAs have been characterized, it may be possible to compare their 
features such as sequence composition and structural elements in order to predict the function 
of other lncRNAs.  However, this will require immense computation power and thus, current 
methods will likely need to be improved. 
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PHOSPHORYLATION OF EZH2 
As discussed in the previous two chapters, regulation of EZH2 function is important 
for normal cell growth.  This is exemplified by the observation that EZH2 is often 
upregulated in the most aggressive cancers.  For this reason, when I began my dissertation 
work, I was interested in understanding how EZH2 function is regulated.  At that time, EZH2 
had been reported to be phosphorylated by Akt which inhibits its HMT activity (Cha et al., 
2005).  Because protein phosphorylation is a well-characterized post-translational 
modification that can impact the function of a protein, I set out to further investigate the role 
of phosphorylation in regulating EZH2 function.   
In Chapter 3, I demonstrate that in addition to the previously reported site, EZH2 is 
threonine phosphorylated which can be regulated by the phosphatases, PP1 and/or PP2A. 
Initial attempts to identify novel EZH2 phosphorylation sites by mass spectrometry were 
unsuccessful.  Therefore, I utilized an approach involving deletion mutant mapping since I 
was able to detect threonine phosphorylation by western blot using a phospho-threonine 
specific antibody.  This strategy allowed me to narrow down the region of EZH2 (aa351-593) 
that was threonine phosphorylated and identify putative sites that could be characterized in 
the future.  While this approach was more laborious, it reflects the difficult nature of 
phosphorylation site identification (see discussion in Chapter 3). 
One particular site, T367, identified through this work was also detected to be 
phosphorylated by high-throughput mass spectrometry (Brill et al., 2009; Chen et al., 2009; 
Huttlin et al., 2010; Malik et al., 2009).  This residue is conserved in humans, mice, and 
zebrafish and is a proline-directed phosphorylation site, making it an attractive site to further 
characterize in the future.  A number of proline-directed kinases exist and their potential role 
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in phosphorylating this residue can be tested through the in vitro assays or specific inhibitors.  
With regard to a functional consequence of T367 phosphorylation (as well as the other four 
threonines identified), it should be noted that these residues do not reside within a functional 
domain of EZH2, but are located in between twin SANT domains which have been 
implicated in DNA and histone tail binding.  This insight provides the basis for future 
experiments involving in vitro gel shift assays using chromatinized DNA to determine if 
phosphorylation of these residues affect their binding to these substrates.   
 
CDK1-MEDIATED PHOSPHORYLATION OF EZH2 
 Chapter 4 focused on two novel EZH2 phosphorylation sites, T345 and T487 which 
were chosen for further characterization on the basis of phosphorylation site prediction 
programs and previous mass spectrometry work (Beausoleil et al., 2004; Choudhary et al., 
2009).  I developed novel phospho-specific antibodies for these sites which were extensively 
validated and used to confirm that T345 and T487 are bona fide EZH2 phosphorylation sites.  
Through in vitro and in vivo experiments, I show that CDK1 can mediate phosphorylation of 
these residues and the consequence of their phosphorylation is that they are targeted for 
ubiquitination and degradation by the proteasome.  Given the importance of EZH2 
regulation, this novel finding nicely illustrates how EZH2 protein levels can be regulated in 
the cell (Figure 4.7). 
 As discussed in Chapter 4, three studies also reported CDK1-mediated 
phosphorylation of EZH2 at T345 and T487 (Chen et al., 2010; Kaneko et al., 2010; Wei et 
al., 2010).  Each study focused on a single site and collectively, it appears that T345 and 
T487 may have distinct functions where pT345 is important for recruitment of the PRC2 to 
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target promoters through enhanced binding to lncRNAs (Chen et al., 2010; Kaneko et al., 
2010), while pT487 inhibits the HMT activity of PRC2 through disrupted EZH2 and SUZ12 
interactions (Wei et al., 2010).  In contrast, my work involved characterizing the role of both 
phosphorylation sites primarily through the use of double mutants.  This caveat is 
exemplified by the cell proliferation disadvantage I observed in the T345A/T487 mutant 
cells.  Chen et al. observed a similar phenotype in T350A (human T345) expressing cell 
while Wei et al. did not observe any effects on cell proliferation in T492A (human T487) 
expressing cells.   Therefore, the compromised cell proliferation phenotype I observed in the 
T345A/T487A expressing cells is most likely due to loss of just T345.  With regard to the 
role of pT345 and pT487 in EZH2 stability, it is likely that both sites play a role in initiating 
the ubiquitination process given that pT345 and pT487 have similar half lives (Figure 4.5A).  
However, this does not preclude the possibility that one phosphorylation site is dominant 
when both sites are phosphorylated.  Thus, future work characterizing the role of the single 
mutants will be necessary to accurately determine the contribution of pT345 and pT487 to 
EZH2 stability.  Additionally, determining the relationship between these two 
phosphorylation sites will also be of interest.  In other words, does phosphorylation of T345 
and T487 occur sequentially?  Does phosphorylation of one residue impact phosphorylation 
of the other residue? 
 Nevertheless, the findings presented in Chapter 4 uncover a novel mechanism 
regarding EZH2 regulation.  We now know that EZH2 proteins levels can be controlled at all 
three levels of the synthesis process (transcription, post-transcription, post-translation).  The 
demonstration that CDK1 can mediate this process is especially interesting given that CDK1 
activities are high in proliferating cells.  It is unclear why degradation of EZH2 is important 
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for cell proliferation.  In fact, it may even be counter-intuitive in light of the knowledge that 
EZH2 represses tumor suppressor genes encoded by CDKN2A.  It is possible that 
degradation of excess EZH2 is important for progression through mitosis although the cell 
cycle profiles of wildtype and T345A/T487A expressing cells are similar (Wei et al., 2010; 
data not shown).  This observation may not be entirely surprising given that knockdown of 
EZH2 leads to roughly a 1.5 fold increase in the percentage of cells in G2/M (Figure 4.2C; 
Varambally et al., 2002).  However, the possibility that T345 and T487 are important for 
mitotic progression can be addressed through rescue experiments using these EZH2 
knockdown cells to determine whether wildtype, but not T345A/T487A, can rescue the 
accumulation of G2/M cells.   
It has become apparent that EZH2 plays a significant role in the development of 
human cancers due to their role in cell proliferation and repression of tumor suppressor 
genes.  Because oncogenesis is no longer thought to be caused solely by genetic mutations 
but also by changes in the epigenome, several pharmaceutical companies are currently 
developing drugs that target EZH2 and other histone methyltransferases (Copeland et al., 
2009).  Thus, understanding how EZH2 is regulated can facilitate the development of novel 
cancer therapies and impact human health. 
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